{ "instance": { "cvs-20230525.htm cvs-20230525_d2.htm": { "axisCustom": 2, "axisStandard": 48, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 3060, "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1080, "dts": { "calculationLink": { "local": [ "cvs-20230525_cal.xml" ] }, "definitionLink": { "local": [ "cvs-20230525_def.xml" ] }, "inline": { "local": [ "cvs-20230525.htm", "cvs-20230525_d2.htm" ] }, "labelLink": { "local": [ "cvs-20230525_lab.xml" ] }, "presentationLink": { "local": [ "cvs-20230525_pre.xml" ] }, "schema": { "local": [ "cvs-20230525.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 1291, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 11, "http://xbrl.sec.gov/dei/2022": 2, "total": 13 }, "keyCustom": 139, "keyStandard": 643, "memberCustom": 126, "memberStandard": 103, "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20230525", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525.htm", "contextRef": "i3fdad821325f486399d0038fd579bc16_D20230525-20230525", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.cvshealth.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525.htm", "contextRef": "i3fdad821325f486399d0038fd579bc16_D20230525-20230525", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.cvshealth.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000100 - Disclosure - Borrowings and Credit Agreements - Long-term Borrowings (Details)", "menuCat": "Details", "order": "100", "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "shortName": "Borrowings and Credit Agreements - Long-term Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ifde94c7f37464b33b3e1498967849d4c_D20210818-20210818", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000101 - Disclosure - Pension Plans and Other Postretirement Benefits - Narrative (Details)", "menuCat": "Details", "order": "101", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i6ae60f8a88824bf889f05cc3b51730b3_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000102 - Disclosure - Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details)", "menuCat": "Details", "order": "102", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "iafd79fc959e44536924c6a9df3de3ae1_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "iafd79fc959e44536924c6a9df3de3ae1_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanInterestCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000103 - Disclosure - Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Cost (Income) (Details)", "menuCat": "Details", "order": "103", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Cost (Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "iafd79fc959e44536924c6a9df3de3ae1_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000104 - Disclosure - Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)", "menuCat": "Details", "order": "104", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i386090869fc94797bcda9d9bd6beaaf4_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000105 - Disclosure - Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details)", "menuCat": "Details", "order": "105", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i5f6a83783837419fbce160a80bfc2d32_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i6ae60f8a88824bf889f05cc3b51730b3_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000106 - Disclosure - Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details)", "menuCat": "Details", "order": "106", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DefinedBenefitPlanPlanAssetsCategoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ic928117af54f4c0892def0fc4bb4ca6f_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i386090869fc94797bcda9d9bd6beaaf4_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000107 - Disclosure - Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)", "menuCat": "Details", "order": "107", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i386090869fc94797bcda9d9bd6beaaf4_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000108 - Disclosure - Income Taxes - Income Tax Provision (Details)", "menuCat": "Details", "order": "108", "role": "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails", "shortName": "Income Taxes - Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000109 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)", "menuCat": "Details", "order": "109", "role": "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "shortName": "Income Taxes - Effective Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Acquisitions, Divestitures and Asset Sales", "menuCat": "Notes", "order": "11", "role": "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSales", "shortName": "Acquisitions, Divestitures and Asset Sales", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000110 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "110", "role": "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000111 - Disclosure - Income Taxes - Narrative (Details)", "menuCat": "Details", "order": "111", "role": "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000112 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)", "menuCat": "Details", "order": "112", "role": "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i68e253af6bf3467aade09b572c1b73a6_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000113 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details)", "menuCat": "Details", "order": "113", "role": "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "shortName": "Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i84d934c3f64d4e02a86157aaa7bdff55_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000114 - Disclosure - Stock Incentive Plans - Restricted Stock Activity (Details)", "menuCat": "Details", "order": "114", "role": "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "shortName": "Stock Incentive Plans - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i84d934c3f64d4e02a86157aaa7bdff55_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromStockOptionsExercised", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000115 - Disclosure - Stock Incentive Plans - Stock Option and SAR Activity (Details)", "menuCat": "Details", "order": "115", "role": "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "shortName": "Stock Incentive Plans - Stock Option and SAR Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ib929cd58d3cb4a4096643aeea5fb40bb_D20220101-20221231", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i5c6c53ae9a7745a09f19b70ba79aa0c2_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000116 - Disclosure - Stock Incentive Plans - Valuation Assumptions (Details)", "menuCat": "Details", "order": "116", "role": "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails", "shortName": "Stock Incentive Plans - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i5c6c53ae9a7745a09f19b70ba79aa0c2_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i6ef83537787945f98e2064fc26ab7c59_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000117 - Disclosure - Shareholders' Equity - Share Repurchases (Details)", "menuCat": "Details", "order": "117", "role": "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails", "shortName": "Shareholders' Equity - Share Repurchases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i6ef83537787945f98e2064fc26ab7c59_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i84ac2198cd22435ba1570e2db00d59e9_I20230104", "decimals": "-8", "first": true, "lang": "en-US", "name": "cvs:AcceleratedShareRepurchasesAgreementAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000118 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details)", "menuCat": "Details", "order": "118", "role": "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "shortName": "Shareholders' Equity - Accelerated Share Repurchases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i84ac2198cd22435ba1570e2db00d59e9_I20230104", "decimals": "-8", "first": true, "lang": "en-US", "name": "cvs:AcceleratedShareRepurchasesAgreementAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "us-gaap:DividendsPayableAmountPerShare", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableAmountPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000119 - Disclosure - Shareholders' Equity - Dividends (Details)", "menuCat": "Details", "order": "119", "role": "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails", "shortName": "Shareholders' Equity - Dividends (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:DividendsPayableAmountPerShare", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableAmountPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Investments", "menuCat": "Notes", "order": "12", "role": "http://www.cvshealth.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000120 - Disclosure - Shareholders' Equity - Regulatory Requirements (Details)", "menuCat": "Details", "order": "120", "role": "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails", "shortName": "Shareholders' Equity - Regulatory Requirements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R121": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000121 - Disclosure - Shareholders' Equity - Noncontrolling Interests (Details)", "menuCat": "Details", "order": "121", "role": "http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails", "shortName": "Shareholders' Equity - Noncontrolling Interests (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R122": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000122 - Disclosure - Other Comprehensive Income (Loss) (Details)", "menuCat": "Details", "order": "122", "role": "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails", "shortName": "Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i88fc675ce48b4c548ef81361fcc6c9d6_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R123": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000123 - Disclosure - Earnings Per Share (Details)", "menuCat": "Details", "order": "123", "role": "http://www.cvshealth.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R124": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "if8b5128a2a36428d980c81abdc2d74c7_D20230101-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "cvs:FourYearsReinsuranceAgreementWithUnrelatedInsurer", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000124 - Disclosure - Reinsurance - Narrative (Details)", "menuCat": "Details", "order": "124", "role": "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "shortName": "Reinsurance - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "if8b5128a2a36428d980c81abdc2d74c7_D20230101-20230131", "decimals": null, "first": true, "lang": "en-US", "name": "cvs:FourYearsReinsuranceAgreementWithUnrelatedInsurer", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R125": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000125 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)", "menuCat": "Details", "order": "125", "role": "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails", "shortName": "Reinsurance - Reinsurance Recoverables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R126": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DirectPremiumsEarned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000126 - Disclosure - Reinsurance - Effects of Reinsurance (Details)", "menuCat": "Details", "order": "126", "role": "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails", "shortName": "Reinsurance - Effects of Reinsurance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DirectPremiumsEarned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R127": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GuaranteeObligationsMaximumExposure", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000127 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "127", "role": "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-8", "lang": "en-US", "name": "cvs:ContractualObligationsToMaintainLevelsOfSeparateAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R128": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000128 - Disclosure - Segment Reporting - Retrospective Adjustments to Segment Composition (Details)", "menuCat": "Details", "order": "128", "role": "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "shortName": "Segment Reporting - Retrospective Adjustments to Segment Composition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i1fdaf8f10b1148d5a53af4de5a2e85e1_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R129": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000129 - Disclosure - Segment Reporting - Narrative (Details)", "menuCat": "Details", "order": "129", "role": "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Fair Value", "menuCat": "Notes", "order": "13", "role": "http://www.cvshealth.com/role/FairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R130": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000130 - Disclosure - Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)", "menuCat": "Details", "order": "130", "role": "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "shortName": "Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i2a07c8633b37492ba109c7cd9a92299a_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R131": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000131 - Disclosure - Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)", "menuCat": "Details", "order": "131", "role": "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "shortName": "Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Goodwill and Other Intangibles", "menuCat": "Notes", "order": "14", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangibles", "shortName": "Goodwill and Other Intangibles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Leases", "menuCat": "Notes", "order": "15", "role": "http://www.cvshealth.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Health Care Costs Payable", "menuCat": "Notes", "order": "16", "role": "http://www.cvshealth.com/role/HealthCareCostsPayable", "shortName": "Health Care Costs Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InsuranceContractAcquisitionCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Other Insurance Liabilities and Separate Accounts", "menuCat": "Notes", "order": "17", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccounts", "shortName": "Other Insurance Liabilities and Separate Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InsuranceContractAcquisitionCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Borrowings and Credit Agreements", "menuCat": "Notes", "order": "18", "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreements", "shortName": "Borrowings and Credit Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Pension Plans and Other Postretirement Benefits", "menuCat": "Notes", "order": "19", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits", "shortName": "Pension Plans and Other Postretirement Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "2", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "20", "role": "http://www.cvshealth.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Stock Incentive Plans", "menuCat": "Notes", "order": "21", "role": "http://www.cvshealth.com/role/StockIncentivePlans", "shortName": "Stock Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Shareholders' Equity", "menuCat": "Notes", "order": "22", "role": "http://www.cvshealth.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Other Comprehensive Income (Loss)", "menuCat": "Notes", "order": "23", "role": "http://www.cvshealth.com/role/OtherComprehensiveIncomeLoss", "shortName": "Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "24", "role": "http://www.cvshealth.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReinsuranceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Reinsurance", "menuCat": "Notes", "order": "25", "role": "http://www.cvshealth.com/role/Reinsurance", "shortName": "Reinsurance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReinsuranceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "26", "role": "http://www.cvshealth.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Segment Reporting", "menuCat": "Notes", "order": "27", "role": "http://www.cvshealth.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "28", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Statements of Comprehensive Income", "menuCat": "Statements", "order": "3", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Acquisitions, Divestitures and Asset Sales (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesTables", "shortName": "Acquisitions, Divestitures and Asset Sales (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "cvs:TotalInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Investments (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.cvshealth.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "cvs:TotalInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Fair Value (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.cvshealth.com/role/FairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Goodwill and Other Intangibles (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables", "shortName": "Goodwill and Other Intangibles (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.cvshealth.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Health Care Costs Payable (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableTables", "shortName": "Health Care Costs Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Other Insurance Liabilities and Separate Accounts (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsTables", "shortName": "Other Insurance Liabilities and Separate Accounts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Borrowings and Credit Agreements (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables", "shortName": "Borrowings and Credit Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Pension Plans and Other Postretirement Benefits (Tables)", "menuCat": "Tables", "order": "38", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables", "shortName": "Pension Plans and Other Postretirement Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "39", "role": "http://www.cvshealth.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "4", "role": "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Stock Incentive Plans (Tables)", "menuCat": "Tables", "order": "40", "role": "http://www.cvshealth.com/role/StockIncentivePlansTables", "shortName": "Stock Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Shareholders' Equity (Tables)", "menuCat": "Tables", "order": "41", "role": "http://www.cvshealth.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Other Comprehensive Income (Tables)", "menuCat": "Tables", "order": "42", "role": "http://www.cvshealth.com/role/OtherComprehensiveIncomeTables", "shortName": "Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "43", "role": "http://www.cvshealth.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Reinsurance (Tables)", "menuCat": "Tables", "order": "44", "role": "http://www.cvshealth.com/role/ReinsuranceTables", "shortName": "Reinsurance (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Segment Reporting (Tables)", "menuCat": "Tables", "order": "45", "role": "http://www.cvshealth.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:NumberOfPharmacyPlanMembers", "reportCount": 1, "unitRef": "people", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Significant Accounting Policies - Narrative (Details)", "menuCat": "Details", "order": "46", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "shortName": "Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Significant Accounting Policies - Cash and Cash Equivalents, Restricted Cash and Cash Equivalents (Details)", "menuCat": "Details", "order": "47", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails", "shortName": "Significant Accounting Policies - Cash and Cash Equivalents, Restricted Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i501f291fb23d49e987222cf13c851afc_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Significant Accounting Policies - Accounts Receivable (Details)", "menuCat": "Details", "order": "48", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "shortName": "Significant Accounting Policies - Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "lang": "en-US", "name": "cvs:VendorandManufacturerReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredPolicyAcquisitionCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredPolicyAcquisitionCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Significant Accounting Policies - Deferred Acquisition Costs (Details)", "menuCat": "Details", "order": "49", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesDeferredAcquisitionCostsDetails", "shortName": "Significant Accounting Policies - Deferred Acquisition Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredPolicyAcquisitionCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DeferredPolicyAcquisitionCostsAdditions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Significant Accounting Policies - Property and Equipment (Details)", "menuCat": "Details", "order": "50", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails", "shortName": "Significant Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Significant Accounting Policies - Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "51", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "shortName": "Significant Accounting Policies - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "iff2a00c33afd4f03b1e2f8fd84299373_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Significant Accounting Policies - Receivables and Contracted Balances (Details)", "menuCat": "Details", "order": "52", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails", "shortName": "Significant Accounting Policies - Receivables and Contracted Balances (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Significant Accounting Policies - Contract Balances (Details)", "menuCat": "Details", "order": "53", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails", "shortName": "Significant Accounting Policies - Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "cvs:ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ConsolidationVariableInterestEntityPolicy", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:ProceedsFromVariableInterestEntity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Significant Accounting Policies - Variable Interest Entities (Details)", "menuCat": "Details", "order": "54", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails", "shortName": "Significant Accounting Policies - Variable Interest Entities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConsolidationVariableInterestEntityPolicy", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:ProceedsFromVariableInterestEntity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i4a8283341305437cbb2e2a1b13edca69_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Significant Accounting Policies - Discontinued Operations (Details)", "menuCat": "Details", "order": "55", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails", "shortName": "Significant Accounting Policies - Discontinued Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i4a8283341305437cbb2e2a1b13edca69_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Acquisitions, Divestitures and Asset Sales - Narrative (Details)", "menuCat": "Details", "order": "56", "role": "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "shortName": "Acquisitions, Divestitures and Asset Sales - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i8941690cb4944d199bf33e6da1cee933_I20230207", "decimals": "2", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i44db5359c9524cc6b84b1886a5fa9bb7_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Acquisitions, Divestitures and Asset Sales - Summary of Assets and Liabilities Held for Sale (Details)", "menuCat": "Details", "order": "57", "role": "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails", "shortName": "Acquisitions, Divestitures and Asset Sales - Summary of Assets and Liabilities Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i44db5359c9524cc6b84b1886a5fa9bb7_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Investments - Schedule of Total Investments (Details)", "menuCat": "Details", "order": "58", "role": "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails", "shortName": "Investments - Schedule of Total Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:TotalInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "lang": "en-US", "name": "cvs:LongTermInvestmentsIncludingAssetsHeldForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Investments - Narrative (Details)", "menuCat": "Details", "order": "59", "role": "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Investments - Debt Securities (Details)", "menuCat": "Details", "order": "60", "role": "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "shortName": "Investments - Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Investments - Debt Securities by Maturity (Details)", "menuCat": "Details", "order": "61", "role": "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "shortName": "Investments - Debt Securities by Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Investments - Unrealized Loss Position (Details)", "menuCat": "Details", "order": "62", "role": "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "shortName": "Investments - Unrealized Loss Position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Investments - Unrealized Loss Position Maturities (Details)", "menuCat": "Details", "order": "63", "role": "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "shortName": "Investments - Unrealized Loss Position Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ActivityInMortgageLoanPortfolioTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ia4afa3728f7a4abe948e80bf8d977e54_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgageLoansOnRealEstateNewMortgageLoans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Investments - Mortgage Loans (Details)", "menuCat": "Details", "order": "64", "role": "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails", "shortName": "Investments - Mortgage Loans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ActivityInMortgageLoanPortfolioTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ia4afa3728f7a4abe948e80bf8d977e54_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgageLoansOnRealEstateNewMortgageLoans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i9ad5913b793d42b68d0dc23a03aeccd7_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgageLoansOnRealEstate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Investments - Mortgage Loans Credit Ratings Indicator (Details)", "menuCat": "Details", "order": "65", "role": "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "shortName": "Investments - Mortgage Loans Credit Ratings Indicator (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i9ad5913b793d42b68d0dc23a03aeccd7_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgageLoansOnRealEstate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i9ad5913b793d42b68d0dc23a03aeccd7_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Investments - Mortgage Loan Principal Repayments (Details)", "menuCat": "Details", "order": "66", "role": "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails", "shortName": "Investments - Mortgage Loan Principal Repayments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i9ad5913b793d42b68d0dc23a03aeccd7_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentIncomeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Investments - Net Investment Income (Details)", "menuCat": "Details", "order": "67", "role": "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "shortName": "Investments - Net Investment Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentIncomeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Investments - Realized Gains (Details)", "menuCat": "Details", "order": "68", "role": "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails", "shortName": "Investments - Realized Gains (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Fair Value - Fair Value Measurements (Details)", "menuCat": "Details", "order": "69", "role": "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "shortName": "Fair Value - Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FinancialLiabilitiesFairValueDisclosure", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ibbd43a9242a0495591196ce21cc7a152_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ic2993c1ba25f447ab89c08c88e66aa96_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Shareholders' Equity", "menuCat": "Statements", "order": "7", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ic2993c1ba25f447ab89c08c88e66aa96_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Fair Value - Changes in Level 3 Financial Assets (Details)", "menuCat": "Details", "order": "70", "role": "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "shortName": "Fair Value - Changes in Level 3 Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ia4ddc4dc69fa45d7b4aabcb366bedfb2_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Fair Value - Gross Transfers Into (Out Of) Level 3 (Details)", "menuCat": "Details", "order": "71", "role": "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "shortName": "Fair Value - Gross Transfers Into (Out Of) Level 3 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "if12cdf7fc62645698e90b515b611256b_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ib998634049ce4ca88cef9c730f1a8c88_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgagesHeldForSaleFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Fair Value - Carrying Value and Fair Value Classified by Level (Details)", "menuCat": "Details", "order": "72", "role": "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "shortName": "Fair Value - Carrying Value and Fair Value Classified by Level (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ib998634049ce4ca88cef9c730f1a8c88_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgagesHeldForSaleFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeparateAccountAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Fair Value - Separate Accounts Fair Value (Details)", "menuCat": "Details", "order": "73", "role": "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "shortName": "Fair Value - Separate Accounts Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i5e061b66c25d4fd5ac6440b36c42c982_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SeparateAccountAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ia4ddc4dc69fa45d7b4aabcb366bedfb2_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Fair Value - Narrative (Details)", "menuCat": "Details", "order": "74", "role": "http://www.cvshealth.com/role/FairValueNarrativeDetails", "shortName": "Fair Value - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i4ecc8bd5e850436fa0683a5a0e40c8c0_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Goodwill and Other Intangibles - Goodwill (Details)", "menuCat": "Details", "order": "75", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "shortName": "Goodwill and Other Intangibles - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ic9bbc9d820604ed98ed4729f6b0aa8f3_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)", "menuCat": "Details", "order": "76", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "shortName": "Goodwill and Other Intangibles - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-8", "lang": "en-US", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Goodwill and Other Intangibles - Intangible Assets (Details)", "menuCat": "Details", "order": "77", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangibles - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)", "menuCat": "Details", "order": "78", "role": "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails", "shortName": "Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Leases - Narrative (Details)", "menuCat": "Details", "order": "79", "role": "http://www.cvshealth.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i4a8283341305437cbb2e2a1b13edca69_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SaleAndLeasebackTransactionGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "cvs:TreasuryStockSharesHeldinTrust", "cvs:TreasuryStockSharesHeldinTrust", "link:footnote", "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i501f291fb23d49e987222cf13c851afc_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:TreasuryStockSharesHeldinTrust", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)", "menuCat": "Statements", "order": "8", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "shortName": "Consolidated Statements of Shareholders' Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "cvs:TreasuryStockValueSharesHeldInTrust", "cvs:TreasuryStockValueSharesHeldInTrust", "link:footnote", "span", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i501f291fb23d49e987222cf13c851afc_I20201231", "decimals": "-6", "lang": "en-US", "name": "cvs:TreasuryStockValueSharesHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Leases - Summary of the Components of Net Lease Cost (Details)", "menuCat": "Details", "order": "80", "role": "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails", "shortName": "Leases - Summary of the Components of Net Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "menuCat": "Details", "order": "81", "role": "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:LesseeLeaseTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)", "menuCat": "Details", "order": "82", "role": "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:LesseeLeaseTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)", "menuCat": "Details", "order": "83", "role": "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Operating and Finance Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ibd901a0e46c140848ccfebccd9919a95_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details)", "menuCat": "Details", "order": "84", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "shortName": "Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ibd901a0e46c140848ccfebccd9919a95_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ibb1ed30851ad423db47b88e42b33cf8f_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Health Care Costs Payable - Narrative (Details)", "menuCat": "Details", "order": "85", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "shortName": "Health Care Costs Payable - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ibb1ed30851ad423db47b88e42b33cf8f_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Health Care Costs Payable - Liability for Unpaid Claims and Claims Adjustment Expense (Details)", "menuCat": "Details", "order": "86", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails", "shortName": "Health Care Costs Payable - Liability for Unpaid Claims and Claims Adjustment Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "ibd901a0e46c140848ccfebccd9919a95_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Health Care Costs Payable - Components of Change in Health Care Costs Payable (Details)", "menuCat": "Details", "order": "87", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "shortName": "Health Care Costs Payable - Components of Change in Health Care Costs Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "if07e27d83137497c9009bcc13d88e451_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Other Insurance Liabilities and Separate Accounts - Narrative (Details)", "menuCat": "Details", "order": "88", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails", "shortName": "Other Insurance Liabilities and Separate Accounts - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "cvs:AccumulatedOtherComprehensiveIncomeLossBeforeTax", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i5bb58d471a7046db9c3cc65f4971e64f_I20210101", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitAfterReinsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LiabilityForFuturePolicyBenefitActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i473c68aa9e4c42a8a8d365737c72ba29_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitAfterReinsurance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - Other Insurance Liabilities and Separate Accounts - Changes in Balances of Long-Duration Insurance Liabilities (Details)", "menuCat": "Details", "order": "89", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "shortName": "Other Insurance Liabilities and Separate Accounts - Changes in Balances of Long-Duration Insurance Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i1263a7bd13e6441c90af49d5dde6fbc0_I20201231", "decimals": "-6", "lang": "en-US", "name": "cvs:LiabilityForFuturePolicyBenefitIncludingDeferredProfitLiabilityExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashDivestedFromDeconsolidation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)", "menuCat": "Statements", "order": "9", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "shortName": "Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashDivestedFromDeconsolidation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000090 - Disclosure - Other Insurance Liabilities and Separate Accounts - Adjustments Resulting From Applying New Accounting Standard (Details)", "menuCat": "Details", "order": "90", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails", "shortName": "Other Insurance Liabilities and Separate Accounts - Adjustments Resulting From Applying New Accounting Standard (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i1fdaf8f10b1148d5a53af4de5a2e85e1_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i0b99c5b96c164850bc3f80f97475b0ae_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000091 - Disclosure - Other Insurance Liabilities and Separate Accounts - Changes in Liability for Future Policy Benefits (Details)", "menuCat": "Details", "order": "91", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails", "shortName": "Other Insurance Liabilities and Separate Accounts - Changes in Liability for Future Policy Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i1263a7bd13e6441c90af49d5dde6fbc0_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i473c68aa9e4c42a8a8d365737c72ba29_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000092 - Disclosure - Other Insurance Liabilities and Separate Accounts - Undiscounted Expected Gross Premiums and Expected Future Benefit Payments (Details)", "menuCat": "Details", "order": "92", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsUndiscountedExpectedGrossPremiumsandExpectedFutureBenefitPaymentsDetails", "shortName": "Other Insurance Liabilities and Separate Accounts - Undiscounted Expected Gross Premiums and Expected Future Benefit Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i473c68aa9e4c42a8a8d365737c72ba29_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i473c68aa9e4c42a8a8d365737c72ba29_I20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000093 - Disclosure - Other Insurance Liabilities and Separate Accounts - Weighted-average Interest Rates and Durations (Details)", "menuCat": "Details", "order": "93", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails", "shortName": "Other Insurance Liabilities and Separate Accounts - Weighted-average Interest Rates and Durations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i473c68aa9e4c42a8a8d365737c72ba29_I20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PolicyholderAccountBalanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PolicyholderFunds", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000094 - Disclosure - Other Insurance Liabilities and Separate Accounts - Roll Forward of Policyholders' Funds (Details)", "menuCat": "Details", "order": "94", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails", "shortName": "Other Insurance Liabilities and Separate Accounts - Roll Forward of Policyholders' Funds (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PolicyholderAccountBalanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i501f291fb23d49e987222cf13c851afc_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PolicyholderFunds", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeparateAccountAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000095 - Disclosure - Other Insurance Liabilities and Separate Accounts - Separate Account Assets (Details)", "menuCat": "Details", "order": "95", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails", "shortName": "Other Insurance Liabilities and Separate Accounts - Separate Account Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i412d46651ee84600b71fc148cc986f29_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SeparateAccountAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SeparateAccountLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i69eed5106b194cac81e8857cca41692b_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeparateAccountsLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000096 - Disclosure - Other Insurance Liabilities and Separate Accounts - Roll Forward of Separate Accounts (Details)", "menuCat": "Details", "order": "96", "role": "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails", "shortName": "Other Insurance Liabilities and Separate Accounts - Roll Forward of Separate Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SeparateAccountLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "idb6445eca93841a3b69baabdc7b0d859_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SeparateAccountLiabilityPremiumAndDeposit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000097 - Disclosure - Borrowings and Credit Agreements - Schedule of Borrowings (Details)", "menuCat": "Details", "order": "97", "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails", "shortName": "Borrowings and Credit Agreements - Schedule of Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedPremium", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000098 - Disclosure - Borrowings and Credit Agreements - Debt Maturities (Details)", "menuCat": "Details", "order": "98", "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails", "shortName": "Borrowings and Credit Agreements - Debt Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000099 - Disclosure - Borrowings and Credit Agreements - Short-term Borrowings (Details)", "menuCat": "Details", "order": "99", "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails", "shortName": "Borrowings and Credit Agreements - Short-term Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20230525_d2.htm", "contextRef": "i656c8f23bf884eb99730c0e0ceed03bb_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 246, "tag": { "cvs_A2021RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Repurchase Program", "label": "2021 Repurchase Program [Member]", "terseLabel": "2021 Repurchase Program" } } }, "localname": "A2021RepurchaseProgramMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "cvs_A2022RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Repurchase Program", "label": "2022 Repurchase Program [Member]", "terseLabel": "2022 Repurchase Program" } } }, "localname": "A2022RepurchaseProgramMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "cvs_AOCIChangeInDiscountRateOnInsuranceReservesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AOCI, Change In Discount Rate On Insurance Reserves", "label": "AOCI, Change In Discount Rate On Insurance Reserves [Member]", "terseLabel": "Change in discount rate on long-duration insurance reserves" } } }, "localname": "AOCIChangeInDiscountRateOnInsuranceReservesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchase Program, Maximum Number Of Shares", "label": "Accelerated Share Repurchase Program, Maximum Number Of Shares", "terseLabel": "ASR, maximum amount of shares received or delivered" } } }, "localname": "AcceleratedShareRepurchaseProgramMaximumNumberOfShares", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "cvs_AcceleratedShareRepurchasesAgreementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases Agreement, Amount", "label": "Accelerated Share Repurchases Agreement, Amount", "terseLabel": "ASR agreement, amount" } } }, "localname": "AcceleratedShareRepurchasesAgreementAmount", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases, Number Of Shares Repurchased", "label": "Accelerated Share Repurchases, Number Of Shares Repurchased", "terseLabel": "Shares repurchased under ASR agreement (in shares)" } } }, "localname": "AcceleratedShareRepurchasesNumberOfSharesRepurchased", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases, Percent Of Notional Amount In Shares To Be Received At End Of Program", "label": "Accelerated Share Repurchases, Percent Of Notional Amount In Shares To Be Received At End Of Program", "terseLabel": "ASR, shares to be received at the end of program as a percent of notional amount" } } }, "localname": "AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "percentItemType" }, "cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases, Percent Of Notional Amount Received In Shares", "label": "Accelerated Share Repurchases, Percent Of Notional Amount Received In Shares", "terseLabel": "ASR percent of notional amount received in shares" } } }, "localname": "AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "percentItemType" }, "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Including Assets Held For Sale", "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Including Assets Held For Sale", "totalLabel": "Total accounts receivable, net" } } }, "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "cvs_AccumulatedOtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated Other Comprehensive Income (Loss), Before Tax", "label": "Accumulated Other Comprehensive Income (Loss), Before Tax", "negatedTerseLabel": "Reduction to accumulated other comprehensive income (loss), before tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_ActivityInMortgageLoanPortfolioTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Table representing activities in mortgage loan portfolio during the period.", "label": "Activity In Mortgage Loan Portfolio [Table Text Block]", "verboseLabel": "Schedule of Activity in Mortgage Loan Portfolio" } } }, "localname": "ActivityInMortgageLoanPortfolioTableTextBlock", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "cvs_AdjustedOperatingIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjusted Operating Income (Loss)", "label": "Adjusted Operating Income (Loss)", "terseLabel": "Adjusted operating income", "verboseLabel": "Adjusted operating income (loss)" } } }, "localname": "AdjustedOperatingIncomeLoss", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails" ], "xbrltype": "monetaryItemType" }, "cvs_AetnaInc2010StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aetna Inc 2010 Stock Incentive Plan [Member]", "label": "Aetna Inc 2010 Stock Incentive Plan [Member]", "terseLabel": "Aetna Inc 2010 Stock Incentive Plan" } } }, "localname": "AetnaInc2010StockIncentivePlanMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "cvs_AllOtherReinsurersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All Other Reinsurers [Member]", "label": "All Other Reinsurers [Member]", "terseLabel": "All Other" } } }, "localname": "AllOtherReinsurersMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "cvs_BackUpCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Back-Up Credit Facilities [Member]", "label": "Back-Up Credit Facilities [Member]", "terseLabel": "Back-Up Credit Facilities" } } }, "localname": "BackUpCreditFacilitiesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_BarclaysBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Barclays Bank", "label": "Barclays Bank [Member]", "terseLabel": "Barclays Bank" } } }, "localname": "BarclaysBankMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "cvs_BswiftLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "bswift LLC", "label": "bswift LLC [Member]", "terseLabel": "bswift LLC" } } }, "localname": "BswiftLLCMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Purchase Price Adjustment, Outside Of Measurement Period", "label": "Business Combination, Purchase Price Adjustment, Outside Of Measurement Period", "negatedTerseLabel": "Acquisition purchase price adjustments outside of measurement period" } } }, "localname": "BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_BusinessCombinationTerminationFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Termination Fee", "label": "Business Combination, Termination Fee", "terseLabel": "Termination fee" } } }, "localname": "BusinessCombinationTerminationFee", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_CVSHealth2017IncentiveCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CVS Health 2017 Incentive Compensation Plan [Member]", "label": "CVS Health 2017 Incentive Compensation Plan [Member]", "terseLabel": "CVS Health 2017 Incentive Compensation Plan" } } }, "localname": "CVSHealth2017IncentiveCompensationPlanMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "cvs_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow, Lessee [Abstract]", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_Categories5And6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage loan credit quality indicator - Categories 5 and 6", "label": "Categories 5 And 6 [Member]", "terseLabel": "5 and 6" } } }, "localname": "Categories5And6Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_Category1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loan Credit Quality Indicator - Category 1 [Member].", "label": "Category 1 [Member]", "terseLabel": "1" } } }, "localname": "Category1Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_Category2To4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loan Credit Quality Indicator - Category 2 to 4 [Member].", "label": "Category 2 To 4 [Member]", "terseLabel": "2 to 4" } } }, "localname": "Category2To4Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_Category7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage loan credit quality indicator - Category 7", "label": "Category 7 [Member]", "terseLabel": "7" } } }, "localname": "Category7Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change In Contract With Customer, Liability", "label": "Change In Contract With Customer, Liability [Roll Forward]", "terseLabel": "Change in Contract with Customer, Liability [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" ], "xbrltype": "stringItemType" }, "cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in operating assets and liabilities, net of effects from acquisitions:", "label": "Change in operating assets and liabilities, net of effects from acquisitions: [Abstract]", "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions:" } } }, "localname": "ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "cvs_CitibankNAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Citibank, N.A.", "label": "Citibank, N.A. [Member]", "terseLabel": "Citibank, N.A." } } }, "localname": "CitibankNAMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "cvs_CommonAndCollectiveTrustsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The total amount of Common/Collective Trusts held by the company, primarily related to investment funds otherwise known as underlying funds.", "label": "Common And Collective Trusts [Member]", "terseLabel": "Common/collective trusts" } } }, "localname": "CommonAndCollectiveTrustsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "domainItemType" }, "cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in contract liability recognized for loyalty program earnings and gift card issuance.", "label": "Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance", "terseLabel": "Rewards earnings and gift card issuances" } } }, "localname": "ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_ContractWithCustomerLiabilityRedemptionAndBreakage": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer Liability Redemption And Breakage", "label": "Contract With Customer Liability Redemption And Breakage", "negatedTerseLabel": "Redemption and breakage" } } }, "localname": "ContractWithCustomerLiabilityRedemptionAndBreakage", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the contractual obligation to maintain the required level of funding in Separate Accounts necessary to fund specific guaranteed pensions annuities.", "label": "Contractual Obligations To Maintain Levels Of Separate Accounts", "terseLabel": "Contractual obligations underlying the guaranteed benefits" } } }, "localname": "ContractualObligationsToMaintainLevelsOfSeparateAccounts", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_CoventryHealthCareWorkersCompensationBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Coventry Health Care Workers Compensation Business", "label": "Coventry Health Care Workers Compensation Business [Member]", "terseLabel": "Coventry Health Care Workers Compensation Business" } } }, "localname": "CoventryHealthCareWorkersCompensationBusinessMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Credit-Related Impairment Loss, Debt Securities, Available-For-Sale, Recognized In Earnings", "label": "Credit-Related Impairment Loss, Debt Securities, Available-For-Sale, Recognized In Earnings", "terseLabel": "Credit-related impairment loss" } } }, "localname": "CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtAndEquitySecuritiesAvailableForSaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments in debt and equity securities which are categorized neither as trading securities nor held-to-maturity securities. Such securities are reported at fair value; unrealized gains and losses related to Available-for-sale securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income)", "label": "Debt And Equity Securities Available For Sale [Member]", "terseLabel": "Debt securities available for sale" } } }, "localname": "DebtAndEquitySecuritiesAvailableForSaleMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "domainItemType" }, "cvs_DebtExtinguishmentFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Extinguishment Fees", "label": "Debt Extinguishment Fees", "terseLabel": "Debt extinguishment fees" } } }, "localname": "DebtExtinguishmentFees", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net", "label": "Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net", "negatedTerseLabel": "Debt discounts and deferred financing costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years", "terseLabel": "After five years through ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss", "terseLabel": "After five years through ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years", "terseLabel": "One year through five years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss", "terseLabel": "One year through five years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years", "terseLabel": "Greater than ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss", "terseLabel": "Greater than ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year", "terseLabel": "Less than one year" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss", "terseLabel": "Less than one year" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Accumulated Loss", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Accumulated Loss", "terseLabel": "Debt securities, maturity, without single maturity date, unrealized losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Fair Value", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Fair Value", "terseLabel": "Debt securities, maturity, without single maturity date, fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]", "label": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities", "label": "Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities", "terseLabel": "Weighted average duration of securities" } } }, "localname": "DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_DeferredTaxAssetsPayrollTaxDeferral": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Payroll Tax Deferral", "label": "Deferred Tax Assets, Payroll Tax Deferral", "terseLabel": "Payroll tax deferral" } } }, "localname": "DeferredTaxAssetsPayrollTaxDeferral", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances", "terseLabel": "Bad debts and other allowances" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DeferredTaxLiabilitiesDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Depreciation and Amortization - Amount of deferred tax liability attributable to taxable temporary differences from depreciation and amortization", "label": "Deferred Tax Liabilities, Depreciation And Amortization", "negatedTerseLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DeferredTaxLiabilitiesRetirementBenefits": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Retirement Benefits", "label": "Deferred Tax Liabilities, Retirement Benefits", "negatedTerseLabel": "Retirement benefits" } } }, "localname": "DeferredTaxLiabilitiesRetirementBenefits", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Common Collective Trust, Debt Securities [Member]", "label": "Defined Benefit Plan, Common Collective Trust, Debt Securities [Member]", "terseLabel": "Common/collective trusts, Debt Securities" } } }, "localname": "DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Common Collective Trust, Equity Securities [Member]", "label": "Defined Benefit Plan, Common Collective Trust, Equity Securities [Member]", "terseLabel": "Common/collective trusts, Equity Securities" } } }, "localname": "DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_DenominatorForEarningsPerShareCalculationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denominator For Earnings Per Share Calculation [Abstract]", "label": "Denominator For Earnings Per Share Calculation [Abstract]", "terseLabel": "Denominator for earnings per share calculation:" } } }, "localname": "DenominatorForEarningsPerShareCalculationAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group, Not Discontinued Operation, Number Of International Health Care Members, Renewal Rights Sold", "label": "Disposal Group, Not Discontinued Operation, Number Of International Health Care Members, Renewal Rights Sold", "terseLabel": "Number of international health care members, renewal rights sold" } } }, "localname": "DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent", "label": "Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent", "terseLabel": "Quarterly dividends declared, percent increase" } } }, "localname": "DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "percentItemType" }, "cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ESPP Issuance, Net Of Treasury Stock, Shares, Acquired, Cost Method", "label": "ESPP Issuance, Net Of Treasury Stock, Shares, Acquired, Cost Method", "terseLabel": "ESPP issuances, net of purchase of treasury shares (in shares)" } } }, "localname": "ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "ESPP Issuance, Net Of Treasury Stock, Value, Acquired, Cost Method", "label": "ESPP Issuance, Net Of Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "ESPP issuances, net of purchase of treasury shares" } } }, "localname": "ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvs_EarningsPerShareBasicAndDilutedEPSAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share, Basic And Diluted EPS", "label": "Earnings Per Share, Basic And Diluted EPS [Abstract]", "terseLabel": "Earnings per share from continuing operations:" } } }, "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "cvs_EffectOfApplicationOfAccountingStandardsUpdate201812AdjustmentsForChangeInDiscountRateAssumptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effect Of Application Of Accounting Standards Update 2018-12, Adjustments For Change In Discount Rate Assumptions", "label": "Effect Of Application Of Accounting Standards Update 2018-12, Adjustments For Change In Discount Rate Assumptions [Member]", "terseLabel": "Change in discount rate assumptions" } } }, "localname": "EffectOfApplicationOfAccountingStandardsUpdate201812AdjustmentsForChangeInDiscountRateAssumptionsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_EffectOfApplicationOfAccountingStandardsUpdate201812AdjustmentsForRemovalOfShadowAdjustmentsInAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effect Of Application Of Accounting Standards Update 2018-12, Adjustments For Removal Of Shadow Adjustments In Accumulated Other Comprehensive Income", "label": "Effect Of Application Of Accounting Standards Update 2018-12, Adjustments For Removal Of Shadow Adjustments In Accumulated Other Comprehensive Income [Member]", "terseLabel": "Removal of shadow adjustments in accumulated other comprehensive income" } } }, "localname": "EffectOfApplicationOfAccountingStandardsUpdate201812AdjustmentsForRemovalOfShadowAdjustmentsInAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal Charges, Percent", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal Charges, Percent", "terseLabel": "Legal charges" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cvs_EmployeeStockOptionsAndStockAppreciationRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Options and Stock Appreciation Rights [Member]", "label": "Employee Stock Options And Stock Appreciation Rights [Member]", "terseLabel": "Employee Stock Options and Stock Appreciation Rights" } } }, "localname": "EmployeeStockOptionsAndStockAppreciationRightsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "domainItemType" }, "cvs_EquitySecuritiesAndCommonAndCollectiveTrustsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Securities And Common And Collective Trusts", "label": "Equity Securities And Common And Collective Trusts [Member]", "terseLabel": "Equity securities and common/collective trusts" } } }, "localname": "EquitySecuritiesAndCommonAndCollectiveTrustsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_EquitySecuritiesDomesticRealEstateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about ownership interests or the right to acquire ownership interests in domestic real estate whose ownership interest is represented by shares of common or preferred stock (which is neither mandatorily redeemable no redeemable at the option of the holder), convertible securities, stock rights, or stock warrants categorized by other type.", "label": "Equity Securities Domestic Real Estate [Member]", "terseLabel": "Domestic real estate" } } }, "localname": "EquitySecuritiesDomesticRealEstateMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract]", "label": "Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract]", "terseLabel": "Net realized and unrealized capital gains (losses):" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "cvs_FederalCourtInOhioJudgmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal Court In Ohio Judgment", "label": "Federal Court In Ohio Judgment [Member]", "terseLabel": "Federal Court in Ohio Judgment" } } }, "localname": "FederalCourtInOhioJudgmentMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance Lease, Assets And Liabilities, Lessee [Abstract]", "label": "Finance Lease, Assets And Liabilities, Lessee [Abstract]", "terseLabel": "Finance leases:" } } }, "localname": "FinanceLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease Cost", "label": "Finance Lease Cost", "totalLabel": "Total finance lease costs" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "cvs_FinanceLeaseRightOfUseAssetNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Accumulated Depreciation", "label": "Finance Lease, Right-Of-Use Asset, Accumulated Depreciation", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedDepreciation", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FinanceLeaseRightOfUseAssetGross": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "cvs_FinanceLeaseRightOfUseAssetNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Gross", "label": "Finance Lease, Right-Of-Use Asset, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "FinanceLeaseRightOfUseAssetGross", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FinanceLeaseRightOfUseAssetNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Net", "label": "Finance Lease, Right-Of-Use Asset, Net", "totalLabel": "Property and equipment, net" } } }, "localname": "FinanceLeaseRightOfUseAssetNet", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the cost, accumulated amortization and net balance of intangibles assets and amortization period, in total and by major class. Finite-lived intangible assets have a stated useful life over which their gross carrying value is amortized. Indefinite intangible assets have a projected indefinite period of benefit (hence are not amortized).", "label": "Finite Lived And Indefinite Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of Intangible Assets" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixtures, Equipment And Internally Developed Software [Member]", "label": "Fixtures, Equipment And Internally Developed Software [Member]", "terseLabel": "Fixtures, equipment and internally developed software" } } }, "localname": "FixturesEquipmentAndInternallyDevelopedSoftwareMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Former Gain Contingency, Recognized In Current Period, Before Tax", "label": "Former Gain Contingency, Recognized In Current Period, Before Tax", "terseLabel": "Former gain contingency, recognized in current period, before tax" } } }, "localname": "FormerGainContingencyRecognizedInCurrentPeriodBeforeTax", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Former Gain Contingency, Recognized In Current Period, Net of Tax", "label": "Former Gain Contingency, Recognized In Current Period, Net of Tax", "terseLabel": "Former gain contingency, recognized in current period, net of tax" } } }, "localname": "FormerGainContingencyRecognizedInCurrentPeriodNetOfTax", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This line item represents the four years of a reinsurance agreement with an unrelated insurer.", "label": "Four Years Reinsurance Agreement With Unrelated Insurer", "terseLabel": "Term of reinsurance agreements with unrelated issuer" } } }, "localname": "FourYearsReinsuranceAgreementWithUnrelatedInsurer", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fresenius Medical Care Reinsurance Company (Cayman) Ltd.", "label": "Fresenius Medical Care Reinsurance Company (Cayman) Ltd. [Member]", "terseLabel": "Fresenius Medical Care Reinsurance Company (Cayman) Ltd." } } }, "localname": "FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "cvs_FrontStoreRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Front Store Revenue [Member]", "label": "Front Store Revenue [Member]", "terseLabel": "Front Store" } } }, "localname": "FrontStoreRevenueMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cvs_GuarantorObligationsNumberOfLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Guarantor Obligations, Number Of Leases", "label": "Guarantor Obligations, Number Of Leases", "terseLabel": "Guarantor obligations, number of leases" } } }, "localname": "GuarantorObligationsNumberOfLeases", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "cvs_HartfordLifeAndAccidentInsuranceCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hartford Life And Accident Insurance Company [Member]", "label": "Hartford Life And Accident Insurance Company [Member]", "terseLabel": "Hartford Life and Accident Insurance Company" } } }, "localname": "HartfordLifeAndAccidentInsuranceCompanyMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care and Other Insurance Liabilities", "label": "Health Care and Other Insurance Liabilities [Abstract]" } } }, "localname": "HealthCareAndOtherInsuranceLiabilitiesAbstract", "nsuri": "http://www.cvshealth.com/20230525", "xbrltype": "stringItemType" }, "cvs_HealthCareBenefitsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Benefits Segment [Member]", "label": "Health Care Benefits Segment [Member]", "terseLabel": "Health Care Benefits" } } }, "localname": "HealthCareBenefitsSegmentMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Costs Payable, Period After Date Of Services Claims Are Paid", "label": "Health Care Costs Payable, Period After Date Of Services Claims Are Paid", "terseLabel": "Period after date of service a claim is paid" } } }, "localname": "HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_HealthInsurerFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the estimated amount of the health insurer fee accrued during the reporting period, as required by Health Care Reform.", "label": "Health Insurer Fee", "terseLabel": "Health insurer fee" } } }, "localname": "HealthInsurerFee", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_HealthInsurerFeeTaxEffectPercent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Represents the tax effect of the health care reform's non-tax deductible health insurer fee.", "label": "Health Insurer Fee Tax Effect, Percent", "terseLabel": "Health insurer fee" } } }, "localname": "HealthInsurerFeeTaxEffectPercent", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cvs_HealthServicesSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Services Segment", "label": "Health Services Segment [Member]", "terseLabel": "Health Services" } } }, "localname": "HealthServicesSegmentMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_HeartlandHealthcareServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Heartland Healthcare Services [Member]", "label": "Heartland Healthcare Services [Member]", "terseLabel": "Heartland Healthcare Services" } } }, "localname": "HeartlandHealthcareServicesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_HeathSavingsAccountBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Heath Savings Account Balance", "label": "Heath Savings Account Balance", "terseLabel": "HSA balances" } } }, "localname": "HeathSavingsAccountBalance", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Public Health Insurance Exchanges, Number Of Additional States", "label": "Individual Public Health Insurance Exchanges, Number Of Additional States", "terseLabel": "Additional number of states in which the Company entered the individual public health insurance exchange" } } }, "localname": "IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Public Health Insurance Exchanges, Number Of States", "label": "Individual Public Health Insurance Exchanges, Number Of States", "terseLabel": "Number of states in which the Company has entered the individual public health insurance exchange" } } }, "localname": "IndividualPublicHealthInsuranceExchangesNumberOfStates", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_InitialContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Initial Contractual Term", "label": "Initial Contractual Term", "terseLabel": "Initial contractual term (in years)" } } }, "localname": "InitialContractualTerm", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "durationItemType" }, "cvs_InsuranceAndHMOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance and HMO subsidiaries [Member].", "label": "Insurance And HMO [Member]", "terseLabel": "Insurance and HMO" } } }, "localname": "InsuranceAndHMOMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "domainItemType" }, "cvs_InsurancePremiumDeficiencyReservePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Premium Deficiency Reserve [Policy Text Block]", "label": "Insurance Premium Deficiency Reserve [Policy Text Block]", "terseLabel": "Premium Deficiency Reserves" } } }, "localname": "InsurancePremiumDeficiencyReservePolicyTextBlock", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intangible Assets, Net (Excluding Goodwill), Including Assets Held For Sale", "label": "Intangible Assets, Net (Excluding Goodwill), Including Assets Held For Sale", "totalLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_InternationalHealthCareRenewalRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International Health Care Renewal Rights", "label": "International Health Care Renewal Rights [Member]", "terseLabel": "International Health Care Renewal Rights" } } }, "localname": "InternationalHealthCareRenewalRightsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Contracts With Fixed Maturity, Fair Value Disclosure.", "label": "Investment Contracts With Fixed Maturity, Fair Value Disclosure", "terseLabel": "Investment contract liabilities with a fixed maturity" } } }, "localname": "InvestmentContractsWithFixedMaturityFairValueDisclosure", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Contracts Without A Fixed Maturity, Fair Value Disclosure.", "label": "Investment Contracts Without A Fixed Maturity, Fair Value Disclosure", "terseLabel": "Investment contracts liabilities without a fixed maturity" } } }, "localname": "InvestmentContractsWithoutFixedMaturityFairValueDisclosure", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "cvs_InvestmentIncomeExcludingCapitalGainsOrLosses": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Income, Excluding Capital Gains Or Losses", "label": "Investment Income, Excluding Capital Gains Or Losses", "totalLabel": "Net investment income (excluding net realized capital gains or losses)" } } }, "localname": "InvestmentIncomeExcludingCapitalGainsOrLosses", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LargeCasePensionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Large Case Pensions", "label": "Large Case Pensions [Member]", "terseLabel": "Large Case Pensions" } } }, "localname": "LargeCasePensionsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsUndiscountedExpectedGrossPremiumsandExpectedFutureBenefitPaymentsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails" ], "xbrltype": "domainItemType" }, "cvs_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability", "label": "Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LeasesWeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases, Weighted Average Discount Rate [Abstract]", "label": "Leases, Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted average discount rate" } } }, "localname": "LeasesWeightedAverageDiscountRateAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_LegalSettlementPeriodOfPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal Settlement, Period Of Payment", "label": "Legal Settlement, Period Of Payment", "terseLabel": "Legal settlement, period of payment" } } }, "localname": "LegalSettlementPeriodOfPayment", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "cvs_LesseeLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Lease [Table Text Block]", "label": "Lessee, Lease [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "LesseeLeaseTableTextBlock", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Leases Liabilities Payments Due [Abstract]", "label": "Lessee, Leases Liabilities Payments Due [Abstract]", "terseLabel": "Total" } } }, "localname": "LesseeLeasesLiabilitiesPaymentsDueAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "cvs_LesseeLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due", "label": "Lessee, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeLiabilityPaymentsDue", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due After Year Five", "label": "Lessee, Liability, Payments, Due After Year Five", "totalLabel": "Thereafter" } } }, "localname": "LesseeLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due Year Five", "label": "Lessee, Liability, Payments, Due Year Five", "totalLabel": "2027" } } }, "localname": "LesseeLiabilityPaymentsDueYearFive", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due Year Four", "label": "Lessee, Liability, Payments, Due Year Four", "totalLabel": "2026" } } }, "localname": "LesseeLiabilityPaymentsDueYearFour", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due Year Three", "label": "Lessee, Liability, Payments, Due Year Three", "totalLabel": "2025" } } }, "localname": "LesseeLiabilityPaymentsDueYearThree", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due Year Two", "label": "Lessee, Liability, Payments, Due Year Two", "totalLabel": "2024" } } }, "localname": "LesseeLiabilityPaymentsDueYearTwo", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsYearOne": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Year One", "label": "Lessee, Liability, Payments, Year One", "totalLabel": "2023" } } }, "localname": "LesseeLiabilityPaymentsYearOne", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Undiscounted Excess Amount", "label": "Lessee, Liability, Undiscounted Excess Amount", "negatedTotalLabel": "Less: imputed interest" } } }, "localname": "LesseeLiabilityUndiscountedExcessAmount", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeOperatingAndFinanceLeasesRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating And Finance Leases, Renewal Term", "label": "Lessee, Operating And Finance Leases, Renewal Term", "terseLabel": "Lease renewal term" } } }, "localname": "LesseeOperatingAndFinanceLeasesRenewalTerm", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_LiabilityForFuturePolicyBenefitAfterReinsuranceNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability For Future Policy Benefit, After Reinsurance, Net Of Tax", "label": "Liability For Future Policy Benefit, After Reinsurance, Net Of Tax", "terseLabel": "Liability for future policy benefits, after tax" } } }, "localname": "LiabilityForFuturePolicyBenefitAfterReinsuranceNetOfTax", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceBeforeDiscountRateChange": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Before Reinsurance, Before Discount Rate Change", "label": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Before Reinsurance, Before Discount Rate Change", "terseLabel": "Liability for future policy benefits, beginning of period - current discount rate" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceBeforeDiscountRateChange", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LiabilityForFuturePolicyBenefitIncludingDeferredProfitLiabilityExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability For Future Policy Benefit, Including Deferred Profit Liability, Expected Future Policy Benefit, Before Reinsurance, After Discount Rate Change", "label": "Liability For Future Policy Benefit, Including Deferred Profit Liability, Expected Future Policy Benefit, Before Reinsurance, After Discount Rate Change", "terseLabel": "Liability for future policy benefits, end of period - current discount rate" } } }, "localname": "LiabilityForFuturePolicyBenefitIncludingDeferredProfitLiabilityExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LiabilityForUnpaidClaims": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the total liability on the balance sheet for unpaid claims for both short-duration and long-duration insurance contracts after reinsurance.", "label": "Liability For Unpaid Claims", "terseLabel": "Liability for unpaid claims" } } }, "localname": "LiabilityForUnpaidClaims", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs", "label": "Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs", "terseLabel": "Benefit costs recorded in other insurance liabilities" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LincolnLifeAnnuityCompanyOfNewYorkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lincoln Life & Annuity Company Of New York [Member]", "label": "Lincoln Life & Annuity Company Of New York [Member]", "terseLabel": "Lincoln Life & Annuity Company of New York" } } }, "localname": "LincolnLifeAnnuityCompanyOfNewYorkMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "cvs_LitigationSettlementNumberOfStatesElectedToJoin": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Number Of States Elected To Join", "label": "Litigation Settlement, Number Of States Elected To Join", "terseLabel": "Number of states that elected to join the settlement" } } }, "localname": "LitigationSettlementNumberOfStatesElectedToJoin", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Number Of States Subject To Earlier Settlements", "label": "Litigation Settlement, Number Of States Subject To Earlier Settlements", "terseLabel": "Number of states subject to earlier settlements" } } }, "localname": "LitigationSettlementNumberOfStatesSubjectToEarlierSettlements", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "cvs_LongTermCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Care", "label": "Long Term Care [Member]", "terseLabel": "Long-Term Care" } } }, "localname": "LongTermCareMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsUndiscountedExpectedGrossPremiumsandExpectedFutureBenefitPaymentsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails" ], "xbrltype": "domainItemType" }, "cvs_LongTermCareReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-Term Care Reporting Unit [Member]", "label": "Long-Term Care Reporting Unit [Member]", "terseLabel": "Long-Term Care Reporting Unit" } } }, "localname": "LongTermCareReportingUnitMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, including liabilities held for sale, classified as noncurrent.", "label": "Long-Term Debt And Lease Obligation, Including Liabilities Held For Sale", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LongTermInvestmentsIncludingAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_Investments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-Term Investments, Including Assets Held For Sale", "label": "Long-Term Investments, Including Assets Held For Sale", "terseLabel": "Long-term" } } }, "localname": "LongTermInvestmentsIncludingAssetsHeldForSale", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LongtermDebtGrossAndLeaseObligation": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Gross And Lease Obligation", "label": "Long-term Debt, Gross And Lease Obligation", "totalLabel": "Total debt principal" } } }, "localname": "LongtermDebtGrossAndLeaseObligation", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents mortgage loans for the reporting period measured at carrying value. We carry the value of our mortgage loan investments on our balance sheet at the unpaid principal balance, net of impairment reserves.", "label": "Mortgage Loans [Member]", "terseLabel": "Mortgage loans" } } }, "localname": "MortgageLoansMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "domainItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal After Year Five", "label": "Mortgage Loans On Real Estate Collections Of Principal After Year Five", "terseLabel": "Thereafter" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months", "label": "Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months", "terseLabel": "2023" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Five", "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Five", "terseLabel": "2027" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Four", "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Four", "terseLabel": "2026" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Three", "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Three", "terseLabel": "2025" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Two", "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Two", "terseLabel": "2024" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateLoansFullyRepaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pertains to amount of mortgage loans fully repaid.", "label": "Mortgage Loans on Real Estate, Loans Fully Repaid", "terseLabel": "Mortgage loans fully repaid" } } }, "localname": "MortgageLoansOnRealEstateLoansFullyRepaid", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateYearOfOriginationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Year Of Origination", "label": "Mortgage Loans On Real Estate Year Of Origination [Axis]", "terseLabel": "Mortgage Loans On Real Estate Year Of Origination [Axis]" } } }, "localname": "MortgageLoansOnRealEstateYearOfOriginationAxis", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "stringItemType" }, "cvs_MortgageLoansOnRealEstateYearOfOriginationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Year Of Origination", "label": "Mortgage Loans On Real Estate Year Of Origination [Domain]", "terseLabel": "Mortgage Loans On Real Estate Year Of Origination [Domain]" } } }, "localname": "MortgageLoansOnRealEstateYearOfOriginationDomain", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_NetRevenuesRetailCoPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Revenues, Retail CoPayments", "label": "Net Revenues, Retail CoPayments", "terseLabel": "Copayments" } } }, "localname": "NetRevenuesRetailCoPayments", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Other Period Increase (Decrease)", "label": "Noncontrolling Interest, Other Period Increase (Decrease)", "terseLabel": "Other increases (decreases) in noncontrolling interests" } } }, "localname": "NoncontrollingInterestOtherPeriodIncreaseDecrease", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvs_NumberOfMedicalMembers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Medical Members", "label": "Number Of Medical Members", "terseLabel": "Number of medical members" } } }, "localname": "NumberOfMedicalMembers", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfPatientsServedPerYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Patients Served Per Year", "label": "Number Of Patients Served Per Year", "terseLabel": "Number of patients served per year (more than)" } } }, "localname": "NumberOfPatientsServedPerYear", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfPeopleServed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of People Served", "label": "Number Of People Served", "terseLabel": "Number of people served" } } }, "localname": "NumberOfPeopleServed", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfPharmacyPlanMembers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Pharmacy Plan Members", "label": "Number Of Pharmacy Plan Members", "terseLabel": "Number of pharmacy plan members" } } }, "localname": "NumberOfPharmacyPlanMembers", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Stores, Annual Planned Closures For Closure Period", "label": "Number Of Stores, Annual Planned Closures For Closure Period", "terseLabel": "Number of stores, annual planned closures for closure period" } } }, "localname": "NumberOfStoresAnnualPlannedClosuresForClosurePeriod", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfStoresPlannedClosure": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Stores, Planned Closure", "label": "Number Of Stores, Planned Closure", "terseLabel": "Number of stores, planned closure" } } }, "localname": "NumberOfStoresPlannedClosure", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfWalkInMedicalClinics": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Walk In Medical Clinics", "label": "Number Of Walk In Medical Clinics", "terseLabel": "Number of walk-in medical clinics (more than)" } } }, "localname": "NumberOfWalkInMedicalClinics", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberofReinsuranceContractsEnteredInto": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reinsurance contracts entered into with an unrelated insurer.", "label": "Number of Reinsurance Contracts Entered Into", "terseLabel": "Number of reinsurance contracts entered into" } } }, "localname": "NumberofReinsuranceContractsEnteredInto", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumeratorForEarningsPerShareCalculationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Numerator For Earnings Per Share Calculation [Abstract]", "label": "Numerator For Earnings Per Share Calculation [Abstract]", "terseLabel": "Numerator for earnings per share calculation:" } } }, "localname": "NumeratorForEarningsPerShareCalculationAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "cvs_OakStreetHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oak Street Health Inc.", "label": "Oak Street Health Inc. [Member]", "terseLabel": "Oak Street Health Inc." } } }, "localname": "OakStreetHealthIncMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_OfficeRealEstateOptimizationCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Office Real Estate Optimization Charges - Related to the abandonment of leased real estate and the related right-of-use assets and property and equipment", "label": "Office Real Estate Optimization Charges", "terseLabel": "Office real estate optimization charges" } } }, "localname": "OfficeRealEstateOptimizationCharges", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OmnicareLongTermCareBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Omnicare Long-Term Care Business", "label": "Omnicare Long-Term Care Business [Member]", "terseLabel": "Omnicare Long-Term Care Business" } } }, "localname": "OmnicareLongTermCareBusinessMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life", "label": "Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life", "terseLabel": "Leases, amount due in excess of remaining estimated economic life" } } }, "localname": "OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Expenses, Excluding Store Impairments, Goodwill Impairments, Loss On Assets Held For Sale, And Loss On Litigation Settlement", "label": "Operating Expenses, Excluding Store Impairments, Goodwill Impairments, Loss On Assets Held For Sale, And Loss On Litigation Settlement", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Assets And Liabilities, Lessee [Abstract]", "label": "Operating Lease, Assets And Liabilities, Lessee [Abstract]", "terseLabel": "Operating leases:" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Liability, Current, Including Liabilities Held For Sale", "label": "Operating Lease, Liability, Current, Including Liabilities Held For Sale", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Liability, Noncurrent, Including Liabilities Held For Sale", "label": "Operating Lease, Liability, Noncurrent, Including Liabilities Held For Sale", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease, Right-of-Use Asset, Fair Value Disclosure", "label": "Operating lease, Right-of-Use Asset, Fair Value Disclosure", "terseLabel": "Operating lease, right-of-use asset, fair value" } } }, "localname": "OperatingLeaseRightOfUseAssetFairValueDisclosure", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right-Of-Use Asset, Including Assets Held For Sale", "label": "Operating Lease, Right-Of-Use Asset, Including Assets Held For Sale", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OtherAcquiredIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Other Acquired Intangible Assets [Line Items]", "terseLabel": "Other Intangible Assets[Line Items]" } } }, "localname": "OtherAcquiredIntangibleAssetsLineItems", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "cvs_OtherAcquiredIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Other Acquired Intangible Assets [Table]", "terseLabel": "Other Intangible Assets [Table]" } } }, "localname": "OtherAcquiredIntangibleAssetsTable", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "cvs_OtherAssetBackedSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by a variety of assets such as automobile loans, credit card receivables, home equity loans, etc.", "label": "Other Asset-Backed Securities [Member]", "terseLabel": "Other asset-backed securities" } } }, "localname": "OtherAssetBackedSecuritiesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_OtherInsuranceLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Insurance Liabilities, Current", "label": "Other Insurance Liabilities, Current", "terseLabel": "Other insurance liabilities" } } }, "localname": "OtherInsuranceLiabilitiesCurrent", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OtherInsuranceLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Insurance Liabilities [Member]", "label": "Other Insurance Liabilities [Member]", "terseLabel": "Other Insurance Liabilities" } } }, "localname": "OtherInsuranceLiabilitiesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_OtherInsuranceLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Insurance Liabilities, Noncurrent", "label": "Other Insurance Liabilities, Noncurrent", "terseLabel": "Other long-term insurance liabilities" } } }, "localname": "OtherInsuranceLiabilitiesNoncurrent", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OtherLongTermInsuranceLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Long-Term Insurance Liabilities [Member]", "label": "Other Long-Term Insurance Liabilities [Member]", "terseLabel": "Other Long-Term Insurance Liabilities" } } }, "localname": "OtherLongTermInsuranceLiabilitiesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_OutstandingSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding Senior Notes [Member]", "label": "Outstanding Senior Notes [Member]", "terseLabel": "Outstanding Senior Notes" } } }, "localname": "OutstandingSeniorNotesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_PayflexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payflex", "label": "Payflex [Member]", "terseLabel": "Payflex" } } }, "localname": "PayflexMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_PaymentsForAcceleratedShareRepurchasesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Accelerated Share Repurchases, Amount", "label": "Payments For Accelerated Share Repurchases, Amount", "terseLabel": "Payments for ASR, amount" } } }, "localname": "PaymentsForAcceleratedShareRepurchasesAmount", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_PaymentsForInsuranceBenefits": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Insurance Benefits", "label": "Payments For Insurance Benefits", "negatedTerseLabel": "Insurance benefits paid" } } }, "localname": "PaymentsForInsuranceBenefits", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies", "label": "Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies", "negatedTerseLabel": "Cash paid for inventory and prescriptions dispensed by retail network pharmacies" } } }, "localname": "PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cvs_PensionAndAnnuityInvestmentContractsInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pension And Annuity Investment Contracts Interest", "label": "Pension And Annuity Investment Contracts Interest", "terseLabel": "Interest rate for pension and annuity investment contracts" } } }, "localname": "PensionAndAnnuityInvestmentContractsInterest", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "cvs_PharmacyAndConsumerHealthSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy And Consumer Health Segment", "label": "Pharmacy And Consumer Health Segment [Member]", "terseLabel": "Pharmacy & Consumer Wellness" } } }, "localname": "PharmacyAndConsumerHealthSegmentMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_PharmacyClaimsAndDiscountsPayableCurrent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pharmacy Claims And Discounts Payable, Current", "label": "Pharmacy Claims And Discounts Payable, Current", "terseLabel": "Pharmacy claims and discounts payable" } } }, "localname": "PharmacyClaimsAndDiscountsPayableCurrent", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvs_PharmacyRebatePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy Rebate Period", "label": "Pharmacy Rebate Period", "terseLabel": "Pharmacy rebate period" } } }, "localname": "PharmacyRebatePeriod", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_PharmacyRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy Revenue [Member]", "label": "Pharmacy Revenue [Member]", "terseLabel": "Pharmacy" } } }, "localname": "PharmacyRevenueMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cvs_PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Policyholder Account Balance, Change In Net Unrealized Gains (Losses)", "label": "Policyholder Account Balance, Change In Net Unrealized Gains (Losses)", "terseLabel": "Change in net unrealized gains (losses)" } } }, "localname": "PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_PolicyholderAccountBalanceDepositsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Policyholder Account Balance, Deposits Received", "label": "Policyholder Account Balance, Deposits Received", "terseLabel": "Deposits received" } } }, "localname": "PolicyholderAccountBalanceDepositsReceived", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_PremiumDeficiencyReserveLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of reserves related to expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), in excess of existing reserves plus anticipated future premiums and reinsurance recoveries.", "label": "Premium Deficiency Reserve Liability", "terseLabel": "Add: Premium deficiency reserve", "verboseLabel": "Premium deficiency reserve" } } }, "localname": "PremiumDeficiencyReserveLiability", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax", "label": "Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax", "terseLabel": "Revenues from external customers", "verboseLabel": "Revenues" } } }, "localname": "PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "cvs_PremiumsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Premiums [Member]", "label": "Premiums [Member]", "terseLabel": "Premiums" } } }, "localname": "PremiumsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item includes proceeds from the sale of debt securities and the related gross realized capital gains and losses, excluding amounts related to experience-rated and discontinued products.", "label": "Proceeds And Related Gross Realized Capital Gains Losses From Sale Of Debt Securities [Table Text Block]", "verboseLabel": "Schedule of Proceeds and Related Gross Realized Capital Gains and Losses From the Sale of Debt Securities" } } }, "localname": "ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "cvs_ProceedsFromVariableInterestEntity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Variable Interest Entity", "label": "Proceeds From Variable Interest Entity", "terseLabel": "Proceeds from VIE" } } }, "localname": "ProceedsFromVariableInterestEntity", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property, Plant And Equipment, Net, Including Assets Held For Sale", "label": "Property, Plant And Equipment, Net, Including Assets Held For Sale", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "cvs_ProviderNetworksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired in a business combination or other transaction. This item represents the value ascribed to the relationships with the acquiree's physicians, hospitals and other health care providers network.", "label": "Provider Networks [Member]", "terseLabel": "Provider networks" } } }, "localname": "ProviderNetworksMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_RadcliffAndFlaimVAetnaIncEtAlMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Radcliff and Flaim v Aetna Inc., et al", "label": "Radcliff and Flaim v Aetna Inc., et al [Member]", "terseLabel": "Radcliff and Flaim v Aetna Inc., et al" } } }, "localname": "RadcliffAndFlaimVAetnaIncEtAlMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "cvs_RedOakMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Red Oak", "label": "Red Oak [Member]", "terseLabel": "Red Oak" } } }, "localname": "RedOakMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_RedeemablePreferredSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Preferred Securities [Member]", "label": "Redeemable Preferred Securities [Member]", "terseLabel": "Redeemable preferred securities" } } }, "localname": "RedeemablePreferredSecuritiesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Charitable Contribution To Non-Profit Entity", "label": "Related Party Transaction, Charitable Contribution To Non-Profit Entity", "terseLabel": "Charitable contribution to CVS Health Foundation" } } }, "localname": "RelatedPartyTransactionCharitableContributionToNonProfitEntity", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units and Performance Share Units [Member]", "label": "Restricted Stock Units And Performance Share Units [Member]", "terseLabel": "Restricted Stock Units and Performance Share Units" } } }, "localname": "RestrictedStockUnitsAndPerformanceShareUnitsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units (RSUs) And Performance Stock Units (PSUs)", "label": "Restricted Stock Units (RSUs) And Performance Stock Units (PSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) and Performance Stock Units (PSUs)" } } }, "localname": "RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "cvs_RetailLongTermCareSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retail Long-Term Care Segment [Member]", "label": "Retail Long-Term Care Segment [Member]", "terseLabel": "Retail LTC" } } }, "localname": "RetailLongTermCareSegmentMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_RevolvingCreditFacilityExpiringMay112026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility, Expiring May 11, 2026", "label": "Revolving Credit Facility, Expiring May 11, 2026 [Member]", "terseLabel": "Revolving Credit Facility, Expiring May 11, 2026" } } }, "localname": "RevolvingCreditFacilityExpiringMay112026Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_RevolvingCreditFacilityExpiringMay162025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility, Expiring May 16, 2025", "label": "Revolving Credit Facility, Expiring May 16, 2025 [Member]", "terseLabel": "Revolving Credit Facility, Expiring May 16, 2025" } } }, "localname": "RevolvingCreditFacilityExpiringMay162025Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_RevolvingCreditFacilityExpiringMay162027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility, Expiring May 16, 2027", "label": "Revolving Credit Facility, Expiring May 16, 2027 [Member]", "terseLabel": "Revolving Credit Facility, Expiring May 16, 2027" } } }, "localname": "RevolvingCreditFacilityExpiringMay162027Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_SalesChannelOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales Channel, Other [Member]", "label": "Sales Channel, Other [Member]", "terseLabel": "Other" } } }, "localname": "SalesChannelOtherMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing credit quality information related to financing receivables by credit quality indicator and by class of financing receivable.", "label": "Schedule Of Mortgage Loan Internal Credit Ratings [Table Text Block]", "verboseLabel": "Schedule of Mortgage Loan Amortized Cost and Credit Quality Indicator" } } }, "localname": "ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "cvs_SeniorNotes1Point3PercentAugust2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 1 Point 3 Percent, August 2027", "label": "Senior Notes, 1 Point 3 Percent, August 2027 [Member]", "terseLabel": "1.3% senior notes due August 2027" } } }, "localname": "SeniorNotes1Point3PercentAugust2027Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes1Point75PercentAugust2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 1 Point 75 Percent, August 2030", "label": "Senior Notes, 1 Point 75 Percent, August 2030 [Member]", "terseLabel": "1.75% senior notes due August 2030" } } }, "localname": "SeniorNotes1Point75PercentAugust2030Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes1Point875PercentFebruary2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 1 Point 875 Percent, February 2031", "label": "Senior Notes, 1 Point 875 Percent, February 2031 [Member]", "terseLabel": "1.875% senior notes due February 2031" } } }, "localname": "SeniorNotes1Point875PercentFebruary2031Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.625DueAugust2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.625%, Due August 2024 [Member]", "label": "Senior Notes, 2.625%, Due August 2024 [Member]", "terseLabel": "2.625% senior notes due August 2024" } } }, "localname": "SeniorNotes2.625DueAugust2024Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.75DueDecember2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.75%, Due December 2022 [Member]", "label": "Senior Notes, 2.75%, Due December 2022 [Member]", "terseLabel": "2.75% senior notes due December 2022" } } }, "localname": "SeniorNotes2.75DueDecember2022Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.75DueNovember2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.75%, Due November 2022 [Member]", "label": "Senior Notes, 2.75%, Due November 2022 [Member]", "terseLabel": "2.75% senior notes due November 2022" } } }, "localname": "SeniorNotes2.75DueNovember2022Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.875DueJune2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.875%, Due June 2026 [Member]", "label": "Senior Notes, 2.875%, Due June 2026 [Member]", "terseLabel": "2.875% senior notes due June 2026" } } }, "localname": "SeniorNotes2.875DueJune2026Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.8DueJune2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.8%, Due June 2023 [Member]", "label": "Senior Notes, 2.8%, Due June 2023 [Member]", "terseLabel": "2.8% senior notes due June 2023" } } }, "localname": "SeniorNotes2.8DueJune2023Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2Point125PercentDueSeptember2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2 Point 125 Percent, Due September 2031", "label": "Senior Notes, 2 Point 125 Percent, Due September 2031 [Member]", "terseLabel": "2.125% senior notes due September 2031" } } }, "localname": "SeniorNotes2Point125PercentDueSeptember2031Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2Point7PercentAugust2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2 Point 7 Percent, August 2040", "label": "Senior Notes, 2 Point 7 Percent, August 2040 [Member]", "terseLabel": "2.7% senior notes due August 2040" } } }, "localname": "SeniorNotes2Point7PercentAugust2040Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.25DueAugust2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.25%, Due August 2029 [Member]", "label": "Senior Notes, 3.25%, Due August 2029 [Member]", "terseLabel": "3.25% senior notes due August 2029" } } }, "localname": "SeniorNotes3.25DueAugust2029Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.375DueAugust2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.375%, Due August 2024 [Member]", "label": "Senior Notes, 3.375%, Due August 2024 [Member]", "terseLabel": "3.375% senior notes due August 2024" } } }, "localname": "SeniorNotes3.375DueAugust2024Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.5DueJuly2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.5%, Due July 2022 [Member]", "label": "Senior Notes, 3.5%, Due July 2022 [Member]", "terseLabel": "3.5% senior notes due July 2022" } } }, "localname": "SeniorNotes3.5DueJuly2022Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.5DueNovember2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.5%, Due November 2024 [Member]", "label": "Senior Notes, 3.5%, Due November 2024 [Member]", "terseLabel": "3.5% senior notes due November 2024" } } }, "localname": "SeniorNotes3.5DueNovember2024Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.7DueMarch2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.7%, Due March 2023 [Member]", "label": "Senior Notes, 3.7%, Due March 2023 [Member]", "terseLabel": "3.7% senior notes due March 2023" } } }, "localname": "SeniorNotes3.7DueMarch2023Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.875DueAugust2047Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.875%, Due August 2047 [Member]", "label": "Senior Notes, 3.875%, Due August 2047 [Member]", "terseLabel": "3.875% senior notes due August 2047" } } }, "localname": "SeniorNotes3.875DueAugust2047Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.875DueJuly2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.875%, Due July 2025 [Member]", "label": "Senior Notes, 3.875%, Due July 2025 [Member]", "terseLabel": "3.875% senior notes due July 2025" } } }, "localname": "SeniorNotes3.875DueJuly2025Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3DueAugust2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3%, Due August 2026 [Member]", "label": "Senior Notes, 3%, Due August 2026 [Member]", "terseLabel": "3% senior notes due August 2026" } } }, "localname": "SeniorNotes3DueAugust2026Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3Point625PercentApril2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3 Point 625 Percent, April 2027", "label": "Senior Notes, 3 Point 625 Percent, April 2027 [Member]", "terseLabel": "3.625% senior notes due April 2027" } } }, "localname": "SeniorNotes3Point625PercentApril2027Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3Point70PercentDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3 Point 70 Percent, Due 2023", "label": "Senior Notes, 3 Point 70 Percent, Due 2023 [Member]", "terseLabel": "3.7% senior notes due 2023" } } }, "localname": "SeniorNotes3Point70PercentDue2023Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3Point75PercentApril2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3 Point 75 Percent, April 2030", "label": "Senior Notes, 3 Point 75 Percent, April 2030 [Member]", "terseLabel": "3.75% senior notes due April 2030" } } }, "localname": "SeniorNotes3Point75PercentApril2030Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.125DueNovember2042Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents senior notes due 2042 with a coupon rate of 4.125%.", "label": "Senior Notes, 4.125%, Due November 2042 [Member]", "terseLabel": "4.125% senior notes due November 2042" } } }, "localname": "SeniorNotes4.125DueNovember2042Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.1DueMarch2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.1%, Due March 2025 [Member]", "label": "Senior Notes, 4.1%, Due March 2025 [Member]", "terseLabel": "4.1% senior notes due March 2025" } } }, "localname": "SeniorNotes4.1DueMarch2025Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.3DueMarch2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.3%, Due March 2028 [Member]", "label": "Senior Notes, 4.3%, Due March 2028 [Member]", "terseLabel": "4.3% senior notes due March 2028" } } }, "localname": "SeniorNotes4.3DueMarch2028Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.5DueMay2042Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.5%, Due May 2042 [Member]", "label": "Senior Notes, 4.5%, Due May 2042 [Member]", "terseLabel": "4.5% senior notes due May 2042" } } }, "localname": "SeniorNotes4.5DueMay2042Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.75DueDecember2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.75%, Due December 2022 [Member]", "label": "Senior Notes, 4.75%, Due December 2022 [Member]", "terseLabel": "4.75% senior notes due December 2022" } } }, "localname": "SeniorNotes4.75DueDecember2022Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.75DueMarch2044Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.75%, Due March 2044 [Member]", "label": "Senior Notes, 4.75%, Due March 2044 [Member]", "terseLabel": "4.75% senior notes due March 2044" } } }, "localname": "SeniorNotes4.75DueMarch2044Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.78DueMarch2038Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.78%, Due March 2038 [Member]", "label": "Senior Notes, 4.78%, Due March 2038 [Member]", "terseLabel": "4.78% senior notes due March 2038" } } }, "localname": "SeniorNotes4.78DueMarch2038Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.875DueJuly2035Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.875%, Due July 2035 [Member]", "label": "Senior Notes, 4.875%, Due July 2035 [Member]", "terseLabel": "4.875% senior notes due July 2035" } } }, "localname": "SeniorNotes4.875DueJuly2035Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes43Due2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.3%, Due 2028", "label": "Senior Notes, 4.3%, Due 2028 [Member]", "terseLabel": "4.3% senior notes due 2028" } } }, "localname": "SeniorNotes43Due2028Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4DueDecember2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4%, Due December 2023 [Member]", "label": "Senior Notes, 4%, Due December 2023 [Member]", "terseLabel": "4% senior notes due December 2023" } } }, "localname": "SeniorNotes4DueDecember2023Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4Point125PercentApril2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4 Point 125 Percent, April 2040", "label": "Senior Notes, 4 Point 125 Percent, April 2040 [Member]", "terseLabel": "4.125% senior notes due April 2040" } } }, "localname": "SeniorNotes4Point125PercentApril2040Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4Point25PercentApril2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4 Point 25 Percent, April 2050", "label": "Senior Notes, 4 Point 25 Percent, April 2050 [Member]", "terseLabel": "4.25% senior notes due April 2050" } } }, "localname": "SeniorNotes4Point25PercentApril2050Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4PointThreePercentDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4 Point Three Percent, Due 2028", "label": "Senior Notes, 4 Point Three Percent, Due 2028 [Member]", "terseLabel": "4.3% senior notes due 2028" } } }, "localname": "SeniorNotes4PointThreePercentDue2028Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5.05DueMarch2048Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.05%, Due March 2048 [Member]", "label": "Senior Notes, 5.05%, Due March 2048 [Member]", "terseLabel": "5.05% senior notes due March 2048" } } }, "localname": "SeniorNotes5.05DueMarch2048Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5.125DueJuly2045Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.125%, Due July 2045 [Member]", "label": "Senior Notes, 5.125%, Due July 2045 [Member]", "terseLabel": "5.125% senior notes due July 2045" } } }, "localname": "SeniorNotes5.125DueJuly2045Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5.3DueDecember2043Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.3%, Due December 2043 [Member]", "label": "Senior Notes, 5.3%, Due December 2043 [Member]", "terseLabel": "5.3% senior notes due December 2043" } } }, "localname": "SeniorNotes5.3DueDecember2043Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5.75DueMay2041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.75%, Due May 2041 [Member]", "label": "Senior Notes, 5.75%, Due May 2041 [Member]", "terseLabel": "5.75% senior notes due May 2041" } } }, "localname": "SeniorNotes5.75DueMay2041Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5DueDecember2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5%, Due December 2024 [Member]", "label": "Senior Notes, 5%, Due December 2024 [Member]", "terseLabel": "5% senior notes due December 2024" } } }, "localname": "SeniorNotes5DueDecember2024Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes6.125DueSeptember2039Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 6.125%, Due September 2039 [Member]", "label": "Senior Notes, 6.125%, Due September 2039 [Member]", "terseLabel": "6.125% senior notes due September 2039" } } }, "localname": "SeniorNotes6.125DueSeptember2039Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes6.25DueJune2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 6.25%, Due June 2027 [Member]", "label": "Senior Notes, 6.25%, Due June 2027 [Member]", "terseLabel": "6.25% senior notes due June 2027" } } }, "localname": "SeniorNotes6.25DueJune2027Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes6.625DueJune2036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 6.625%, Due June 2036 [Member]", "label": "Senior Notes, 6.625%, Due June 2036 [Member]", "terseLabel": "6.625% senior notes due June 2036" } } }, "localname": "SeniorNotes6.625DueJune2036Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes6.75DueDecember2037Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 6.75%, Due December 2037 [Member]", "label": "Senior Notes, 6.75%, Due December 2037 [Member]", "terseLabel": "6.75% senior notes due December 2037" } } }, "localname": "SeniorNotes6.75DueDecember2037Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeparateAccountFinancialAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Separate Account, Financial Assets", "label": "Separate Account, Financial Assets [Member]", "terseLabel": "Separate Accounts, financial assets" } } }, "localname": "SeparateAccountFinancialAssetsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/FairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_SeparateAccountOtherAssetBackedSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Separate Account, Other Asset-Backed Securities", "label": "Separate Account, Other Asset-Backed Securities [Member]", "terseLabel": "Other asset-backed securities" } } }, "localname": "SeparateAccountOtherAssetBackedSecuritiesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement Framework And Other Opioid-Related Claims", "label": "Settlement Framework And Other Opioid-Related Claims [Member]", "terseLabel": "Settlement Framework and Other Opioid-Related Claims" } } }, "localname": "SettlementFrameworkAndOtherOpioidRelatedClaimsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "cvs_SettlementFrameworkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement Framework", "label": "Settlement Framework [Member]", "terseLabel": "Settlement Framework" } } }, "localname": "SettlementFrameworkMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Actual Payout Rates", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Actual Payout Rates", "terseLabel": "Restricted stock units and performance stock units vested if actual payout rates are applied (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value", "terseLabel": "Fair value of stock options and SARs vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number", "terseLabel": "Expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Option, Granted Prior Through 2018", "label": "Share-Based Payment Arrangement, Option, Granted Prior Through 2018 [Member]", "terseLabel": "Stock options granted through 2018" } } }, "localname": "ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "domainItemType" }, "cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Option, Granted Subsequent to 2018", "label": "Share-Based Payment Arrangement, Option, Granted Subsequent to 2018 [Member]", "terseLabel": "Stock options granted subsequent to 2018" } } }, "localname": "ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "domainItemType" }, "cvs_SharesHeldInTrustPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Held In Trust [Policy Text Block]", "label": "Shares Held In Trust [Policy Text Block]", "terseLabel": "Shares Held in Trust" } } }, "localname": "SharesHeldInTrustPolicyTextBlock", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvs_SignifyHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Signify Health, Inc.", "label": "Signify Health, Inc. [Member]", "terseLabel": "Signify Health, Inc." } } }, "localname": "SignifyHealthIncMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_StateOfFloridaSettlementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State Of Florida Settlement", "label": "State Of Florida Settlement [Member]", "terseLabel": "State of Florida Settlement" } } }, "localname": "StateOfFloridaSettlementMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased", "label": "Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased", "terseLabel": "Average purchase price of shares purchased (in dollars per share)" } } }, "localname": "StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "perShareItemType" }, "cvs_StockOptionsAndStockAppreciationRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options And Stock Appreciation Rights", "label": "Stock Options And Stock Appreciation Rights [Member]", "terseLabel": "Stock Options and Stock Appreciation Rights" } } }, "localname": "StockOptionsAndStockAppreciationRightsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "cvs_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestPretax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity, Including Portion Attributable To Noncontrolling Interest, Pretax", "label": "Stockholders' Equity, Including Portion Attributable To Noncontrolling Interest, Pretax", "terseLabel": "Adoption of new accounting standard, pre-tax" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestPretax", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "cvs_StoreImpairmentCharges": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Store Impairment Charges", "label": "Store Impairment Charges", "terseLabel": "Store impairments", "verboseLabel": "Store impairment charges" } } }, "localname": "StoreImpairmentCharges", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_SupportingExperienceRatedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supporting discontinued and experience-rated products.", "label": "Supporting Experience Rated Products [Member]", "terseLabel": "Supporting experience- rated products" } } }, "localname": "SupportingExperienceRatedProductsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_SupportingRemainingProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt securities in an unrealized capital loss position supporting remaining products.", "label": "Supporting Remaining Products [Member]", "terseLabel": "Supporting remaining products" } } }, "localname": "SupportingRemainingProductsMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_ThailandBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thailand Business", "label": "Thailand Business [Member]", "terseLabel": "Thailand Business" } } }, "localname": "ThailandBusinessMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_TotalInvestmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Investments [Axis]", "terseLabel": "Total Investments [Axis]" } } }, "localname": "TotalInvestmentsAxis", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "stringItemType" }, "cvs_TotalInvestmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Investments [Domain]", "terseLabel": "Total Investments [Domain]" } } }, "localname": "TotalInvestmentsDomain", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "domainItemType" }, "cvs_TotalInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Investments [Line Items]", "terseLabel": "Total Investments [Line Items]" } } }, "localname": "TotalInvestmentsLineItems", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "stringItemType" }, "cvs_TotalInvestmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Investments [Table]", "terseLabel": "Total Investments [Table]" } } }, "localname": "TotalInvestmentsTable", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "stringItemType" }, "cvs_TotalInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item includes total investments, both current and long-term.", "label": "Total Investments [Table Text Block]", "verboseLabel": "Schedule of Total Investments" } } }, "localname": "TotalInvestmentsTableTextBlock", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "cvs_TransferOfSharesToTreasuryStockValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transfer Of Shares To Treasury Stock Value", "label": "Transfer Of Shares To Treasury Stock Value", "terseLabel": "Transfer of shares to treasury stock value" } } }, "localname": "TransferOfSharesToTreasuryStockValue", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance", "label": "Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance", "negatedTerseLabel": "Purchase of treasury shares, net of ESPP issuances (in shares)" } } }, "localname": "TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "cvs_TreasuryStockSharesHeldinTrust": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Shares, Held in Trust", "label": "Treasury Stock, Shares, Held in Trust", "terseLabel": "Treasury shares held in trust (in shares)" } } }, "localname": "TreasuryStockSharesHeldinTrust", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance", "label": "Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance", "negatedTerseLabel": "Purchase of treasury shares, net of ESPP issuances" } } }, "localname": "TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvs_TreasuryStockValueSharesHeldInTrust": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Value, Shares Held In Trust", "label": "Treasury Stock, Value, Shares Held In Trust", "terseLabel": "Treasury shares held in trust" } } }, "localname": "TreasuryStockValueSharesHeldInTrust", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "monetaryItemType" }, "cvs_TribalEntitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tribal Entities", "label": "Tribal Entities [Member]", "terseLabel": "Tribal Entities" } } }, "localname": "TribalEntitiesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Department Of Health And Human Services, ACA Risk Corridor Receivables", "label": "U.S. Department Of Health And Human Services, ACA Risk Corridor Receivables [Member]", "terseLabel": "U.S. Department of Health and Human Services, ACA Risk Corridor Receivables" } } }, "localname": "USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_USFederalGovernmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US Federal Government", "label": "US Federal Government [Member]", "terseLabel": "US Federal Government" } } }, "localname": "USFederalGovernmentMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_VOYARetirementInsuranceAndAnnuityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VOYA Retirement Insurance And Annuity Company [Member]", "label": "VOYA Retirement Insurance And Annuity Company [Member]", "terseLabel": "VOYA Retirement Insurance and Annuity Company" } } }, "localname": "VOYARetirementInsuranceAndAnnuityCompanyMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "cvs_ValueOfBusinessAcquiredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value Of Business Acquired [Member]", "label": "Value Of Business Acquired [Member]", "terseLabel": "Value of Business Acquired" } } }, "localname": "ValueOfBusinessAcquiredMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_VariableInterestEntityAmendedContractExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Amended Contract Extension Term", "label": "Variable Interest Entity, Amended Contract Extension Term", "terseLabel": "Amended contract extension term" } } }, "localname": "VariableInterestEntityAmendedContractExtensionTerm", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "durationItemType" }, "cvs_VariableInterestEntityAmendedContractTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Amended Contract Term", "label": "Variable Interest Entity, Amended Contract Term", "terseLabel": "Amended contract term (in years)" } } }, "localname": "VariableInterestEntityAmendedContractTerm", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "durationItemType" }, "cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor Allowances And Purchase Discounts", "label": "Vendor Allowances And Purchase Discounts [Policy Text Block]", "terseLabel": "Vendor Allowances and Purchase Discounts" } } }, "localname": "VendorAllowancesAndPurchaseDiscountsPolicyTextBlock", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvs_VendorandManufacturerReceivables": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": 1.0, "parentTag": "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Vendor and Manufacturer Receivables", "label": "Vendor and Manufacturer Receivables", "terseLabel": "Vendor and manufacturer receivables" } } }, "localname": "VendorandManufacturerReceivables", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "cvs_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Lease Term [Abstract]", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_YearOfOriginationPeriodFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period Five", "label": "Year Of Origination Period Five [Member]", "terseLabel": "2018" } } }, "localname": "YearOfOriginationPeriodFiveMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPeriodFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period Four", "label": "Year Of Origination Period Four [Member]", "terseLabel": "2019" } } }, "localname": "YearOfOriginationPeriodFourMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period One", "label": "Year Of Origination Period One [Member]", "terseLabel": "2022" } } }, "localname": "YearOfOriginationPeriodOneMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period Three", "label": "Year Of Origination Period Three [Member]", "terseLabel": "2020" } } }, "localname": "YearOfOriginationPeriodThreeMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period Two", "label": "Year Of Origination Period Two [Member]", "terseLabel": "2021" } } }, "localname": "YearOfOriginationPeriodTwoMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPriorToPeriodFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Prior To Period Five", "label": "Year Of Origination Prior To Period Five [Member]", "terseLabel": "Prior" } } }, "localname": "YearOfOriginationPriorToPeriodFiveMember", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings", "label": "Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings", "terseLabel": "Yield-related impairment loss" } } }, "localname": "YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "nsuri": "http://www.cvshealth.com/20230525", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1198" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1198" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1198" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1198" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1200" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r1201" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1197" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1199" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r1202" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r1203" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r421", "r825", "r826", "r831", "r832", "r920", "r1096", "r1101", "r1283", "r1286", "r1287", "r1384", "r1387", "r1388" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r421", "r825", "r826", "r831", "r832", "r920", "r1096", "r1101", "r1283", "r1286", "r1287", "r1384", "r1387", "r1388" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r421", "r467", "r485", "r486", "r487", "r488", "r489", "r491", "r495", "r584", "r585", "r586", "r587", "r589", "r590", "r592", "r594", "r595", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1284", "r1285", "r1385", "r1386" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r421", "r467", "r485", "r486", "r487", "r488", "r489", "r491", "r495", "r584", "r585", "r586", "r587", "r589", "r590", "r592", "r594", "r595", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1284", "r1285", "r1385", "r1386" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r418", "r419", "r600", "r627", "r1122", "r1126", "r1128" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r355", "r426", "r434", "r441", "r531", "r773", "r774", "r775", "r806", "r807", "r839", "r842", "r844", "r845", "r917" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r355", "r426", "r434", "r441", "r531", "r773", "r774", "r775", "r806", "r807", "r839", "r842", "r844", "r845", "r917" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r355", "r426", "r434", "r441", "r531", "r773", "r774", "r775", "r806", "r807", "r839", "r842", "r844", "r845", "r917" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r500", "r1150", "r1292", "r1369" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r580", "r581", "r582", "r583", "r731", "r955", "r1025", "r1097", "r1098", "r1147", "r1165", "r1188", "r1288", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r580", "r581", "r582", "r583", "r731", "r955", "r1025", "r1097", "r1098", "r1147", "r1165", "r1188", "r1288", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r1075", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1100", "r1102" ], "lang": { "en-us": { "role": { "documentation": "Information by type of real estate property.", "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]", "terseLabel": "Mortgage Loans on Real Estate [Line Items]" } } }, "localname": "MortgageLoansOnRealEstateLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [ "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1100", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110" ], "lang": { "en-us": { "role": { "documentation": "Land and any structures permanently fixed to it.", "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateScheduleTable": { "auth_ref": [ "r1077", "r1112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table]", "terseLabel": "Mortgage Loans on Real Estate [Table]" } } }, "localname": "MortgageLoansOnRealEstateScheduleTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r500", "r1150", "r1292", "r1369" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r497", "r957", "r1148", "r1176", "r1279", "r1280", "r1292", "r1365" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsUndiscountedExpectedGrossPremiumsandExpectedFutureBenefitPaymentsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r497", "r957", "r1148", "r1176", "r1279", "r1280", "r1292", "r1365" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsUndiscountedExpectedGrossPremiumsandExpectedFutureBenefitPaymentsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r580", "r581", "r582", "r583", "r681", "r731", "r764", "r765", "r766", "r928", "r955", "r1025", "r1097", "r1098", "r1147", "r1165", "r1188", "r1275", "r1288", "r1353", "r1354", "r1355", "r1356", "r1357" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r580", "r581", "r582", "r583", "r681", "r731", "r764", "r765", "r766", "r928", "r955", "r1025", "r1097", "r1098", "r1147", "r1165", "r1188", "r1275", "r1288", "r1353", "r1354", "r1355", "r1356", "r1357" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r418", "r419", "r600", "r627", "r1127", "r1128" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r423", "r424", "r425", "r436", "r437", "r455", "r844", "r845", "r1228", "r1229", "r1231", "r1232", "r1234", "r1238", "r1239" ], "lang": { "en-us": { "role": { "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period, Adjustment [Member]", "terseLabel": "Adjustments" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r356", "r423", "r424", "r425", "r427", "r428", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r455", "r532", "r533", "r807", "r840", "r844", "r845", "r846", "r889", "r918", "r919", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ], "lang": { "en-us": { "role": { "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r356", "r423", "r424", "r425", "r427", "r428", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r455", "r532", "r533", "r807", "r840", "r844", "r845", "r846", "r889", "r918", "r919", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ], "lang": { "en-us": { "role": { "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": { "auth_ref": [ "r356", "r427", "r428", "r434", "r441", "r532", "r533", "r807", "r840", "r846", "r889", "r918", "r919", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ], "lang": { "en-us": { "role": { "documentation": "Cumulative increase (decrease) to previously issued financial statements for retrospective application of amendment to accounting standards and adjustment for reclassification from amendment to accounting standards.", "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]", "terseLabel": "Adjustments" } } }, "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r732", "r1235", "r1383" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r356", "r423", "r425", "r427", "r428", "r431", "r432", "r440", "r455", "r807", "r840", "r844", "r845", "r889", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1233", "r1234", "r1236", "r1237", "r1238", "r1258", "r1259", "r1339", "r1348", "r1349" ], "lang": { "en-us": { "role": { "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Previously Reported [Member]", "terseLabel": "As Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r441", "r732", "r1204", "r1235" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r441", "r732", "r1204", "r1205", "r1235" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock": { "auth_ref": [ "r1001", "r1111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the supplemental schedule of reinsurance information. Reinsurance schedule includes, but is not limited to, the type of insurance, gross amount of premiums, premiums ceded to other entities, premiums assumed from other entities, net amount of premium revenue, and the percentage of the premiums assumed to net premium revenue.", "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Text Block]", "terseLabel": "Schedule of Direct, Assumed and Ceded Premiums Earned" } } }, "localname": "SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASU 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201812Member": { "auth_ref": [ "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-12 Financial Services-Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts.", "label": "Accounting Standards Update 2018-12 [Member]", "terseLabel": "Accounting Standards Update 2018-12" } } }, "localname": "AccountingStandardsUpdate201812Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r353", "r354", "r355", "r356", "r357", "r427", "r428", "r429", "r505", "r506", "r528", "r529", "r530", "r531", "r532", "r533", "r773", "r774", "r775", "r806", "r807", "r821", "r822", "r823", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r882", "r883", "r886", "r887", "r888", "r914", "r915", "r916", "r917", "r918", "r919", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1230" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]", "terseLabel": "Other payables" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r23", "r40" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r1081" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Other receivables" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r502", "r503" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r58", "r63", "r231", "r392", "r1210", "r1211" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r157", "r367" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r57", "r63", "r231", "r392", "r1210", "r1211" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r385", "r392", "r829", "r1210", "r1211" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Net cash flow hedges" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r380", "r381", "r382", "r385", "r392", "r1210", "r1211" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]", "terseLabel": "Net unrealized investment gains (losses)" } } }, "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r61", "r62", "r63", "r373", "r987", "r1033", "r1037" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "negatedTerseLabel": "Reduction to accumulated other comprehensive income (loss)", "verboseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r60", "r63", "r231", "r919", "r1028", "r1029", "r1209", "r1210", "r1211", "r1225", "r1226", "r1227" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]", "terseLabel": "Condensed Consolidated Statement of Cash Flows:" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r353", "r354", "r355", "r356", "r357", "r427", "r428", "r429", "r430", "r441", "r505", "r506", "r528", "r529", "r530", "r531", "r532", "r533", "r773", "r774", "r775", "r804", "r805", "r806", "r807", "r821", "r822", "r823", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r882", "r883", "r886", "r887", "r888", "r889", "r914", "r915", "r916", "r917", "r918", "r919", "r959", "r960", "r961", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments required to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r779" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r768" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocationsToPolicyholdersPolicies": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining amounts of income and expenses allocated to policyholders and contract holders, excluding the method for determining dividends payable to policyholders and accounting policies pertaining to separate accounts for variable annuity contracts.", "label": "Allocations to Policyholders, Policies [Policy Text Block]", "terseLabel": "Policyholders' Funds" } } }, "localname": "AllocationsToPolicyholdersPolicies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r374", "r504", "r534", "r536", "r538" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "auth_ref": [ "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.", "label": "Accounts Receivable, Allowance for Credit Loss, Recovery", "negatedTerseLabel": "Receipt of fully reserved ACA risk corridor receivable" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r93", "r140", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive securities excluded from computation of EPS (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r60", "r63", "r231", "r1209", "r1210", "r1211" ], "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax": { "auth_ref": [ "r1183", "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "weight": 1.0 }, "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in expected future policy benefit component of liability for future policy benefit from change in discount rate.", "label": "AOCI, Liability for Future Policy Benefit, Expected Future Policy Benefit, before Tax", "negatedPeriodEndLabel": "Add: Impact of discount rate on long-duration insurance reserves", "negatedPeriodStartLabel": "Less: Impact of discount rate on long-duration insurance reserves", "negatedTerseLabel": "Effect of changes in discount rate assumptions" } } }, "localname": "AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax": { "auth_ref": [ "r1183", "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from increase (decrease) in expected net premium component of liability for future policy benefit from change in discount rate.", "label": "AOCI, Liability for Future Policy Benefit, Expected Net Premium, before Tax", "terseLabel": "Effect of changes in discount rate assumptions" } } }, "localname": "AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r1155", "r1251" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-Backed Securities [Member]", "terseLabel": "Other asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r277", "r304", "r371", "r415", "r475", "r487", "r493", "r526", "r584", "r585", "r587", "r588", "r589", "r591", "r593", "r595", "r596", "r825", "r831", "r864", "r1173", "r1284", "r1285", "r1350" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r361", "r378", "r415", "r526", "r584", "r585", "r587", "r588", "r589", "r591", "r593", "r595", "r596", "r825", "r831", "r864", "r1173", "r1284", "r1285", "r1350" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "terseLabel": "Total current assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r256" ], "calculation": { "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldByInsuranceRegulators": { "auth_ref": [ "r1054" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of cash and investment securities on deposit with state regulatory authorities in connection with capital requirements.", "label": "Assets Held by Insurance Regulators", "terseLabel": "Investments on deposit with regulatory bodies" } } }, "localname": "AssetsHeldByInsuranceRegulators", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r15", "r159", "r359", "r360" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r15", "r154", "r159", "r359", "r360" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssumedPremiumsEarned": { "auth_ref": [ "r317", "r999", "r1042", "r1045" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 2.0, "parentTag": "us-gaap_PremiumsEarnedNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of earned premiums assumed from other entities.", "label": "Assumed Premiums Earned", "terseLabel": "Assumed" } } }, "localname": "AssumedPremiumsEarned", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r127" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r128" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r508", "r543" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Gross Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]", "terseLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r132" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "terseLabel": "After five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r129", "r512", "r975" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "terseLabel": "After five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r131" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "One year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r129", "r511", "r974" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "One year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "auth_ref": [ "r133" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10", "terseLabel": "Greater than ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "auth_ref": [ "r129", "r513", "r976" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10", "terseLabel": "Greater than ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r130" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r129", "r510", "r973" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": { "auth_ref": [ "r514" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost", "terseLabel": "Debt securities, maturity, without single maturity date" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "auth_ref": [ "r134", "r977" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value", "terseLabel": "Debt securities, maturity, without single maturity date" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r126", "r507", "r543", "r964" ], "calculation": { "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 }, "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Debt securities", "totalLabel": "Total", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]", "terseLabel": "Number of Securities" } } }, "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r739", "r740", "r741", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r763", "r764", "r765", "r766", "r767" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r248", "r251" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Condensed Consolidated Balance Sheet:" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings, building improvements and leasehold improvements", "verboseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Distribution centers and Corporate offices" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r820", "r1159", "r1162" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r217", "r218", "r820", "r1159", "r1162" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Cash to be received by shareholders in proposed/pending acquisition (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r220", "r221", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total value of proposed/pending acquisition" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "verboseLabel": "Acquisition-related integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.", "label": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]", "terseLabel": "Health Care Contract Acquisition Costs" } } }, "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r95", "r364", "r1123" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r96", "r275" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r88", "r95", "r99" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period", "totalLabel": "Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r88", "r267" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDivestedFromDeconsolidation": { "auth_ref": [ "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.", "label": "Cash Divested from Deconsolidation", "terseLabel": "Cash and restricted cash sold" } } }, "localname": "CashDivestedFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries": { "auth_ref": [ "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents disclosure of the aggregate cash dividends paid to the entity by consolidated subsidiaries.", "label": "SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Consolidated Subsidiaries", "terseLabel": "Dividends paid" } } }, "localname": "CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.", "label": "Cash Proceeds Received and Tax Benefit from Share-Based Payment Awards [Table Text Block]", "terseLabel": "Summary of Stock Option and SAR Activity" } } }, "localname": "CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashSurrenderValueDuePolicyholdersAmount": { "auth_ref": [ "r1023", "r1188" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash to be paid to policyholder upon termination and surrender of long-duration contract issued by insurance entity.", "label": "Policyholder Account Balance, Cash Surrender Value", "terseLabel": "Cash surrender value" } } }, "localname": "CashSurrenderValueDuePolicyholdersAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CededCreditRiskAxis": { "auth_ref": [ "r1359", "r1375" ], "lang": { "en-us": { "role": { "documentation": "Information by name of reinsurer or group of reinsurers in reinsurance contract.", "label": "Reinsurer, Name [Axis]", "terseLabel": "Ceded Credit Risk, Reinsurer [Axis]" } } }, "localname": "CededCreditRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CededCreditRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Ceded Credit Risk [Line Items]", "terseLabel": "Ceded Credit Risk [Line Items]" } } }, "localname": "CededCreditRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CededCreditRiskReinsurerDomain": { "auth_ref": [ "r1359" ], "lang": { "en-us": { "role": { "documentation": "Name of reinsurer or group of reinsurers in reinsurance contract.", "label": "Reinsurer, Name [Domain]", "terseLabel": "Ceded Credit Risk, Reinsurer [Domain]" } } }, "localname": "CededCreditRiskReinsurerDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CededCreditRiskTable": { "auth_ref": [ "r1056" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.", "label": "Ceded Credit Risk [Table]", "terseLabel": "Ceded Credit Risk [Table]" } } }, "localname": "CededCreditRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CededPremiumsEarned": { "auth_ref": [ "r317", "r998", "r1039", "r1040", "r1043", "r1045" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 3.0, "parentTag": "us-gaap_PremiumsEarnedNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earned premiums ceded to other entities.", "label": "Ceded Premiums Earned", "negatedTerseLabel": "Ceded" } } }, "localname": "CededPremiumsEarned", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]", "terseLabel": "Change in Contract with Customer, Liability [Abstract]" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClaimsDevelopmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Claims Development [Line Items]", "terseLabel": "Claims Development [Line Items]" } } }, "localname": "ClaimsDevelopmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r179", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "auth_ref": [ "r134", "r1296" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by commercial real estate mortgage loans.", "label": "Commercial Mortgage-Backed Securities [Member]", "terseLabel": "Commercial mortgage-backed securities" } } }, "localname": "CommercialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialRealEstateMember": { "auth_ref": [ "r1136", "r1296" ], "lang": { "en-us": { "role": { "documentation": "Property that is solely used for business purposes.", "label": "Commercial Real Estate [Member]", "terseLabel": "Commercial Real Estate" } } }, "localname": "CommercialRealEstateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r286", "r311" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 17)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r162", "r577", "r578", "r1083", "r1282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Capital shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).", "label": "Common Stock Including Additional Paid in Capital [Member]", "terseLabel": "Common Stock and Capital Surplus" } } }, "localname": "CommonStockIncludingAdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r1225", "r1226", "r1338" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r34", "r173" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r34", "r1173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": { "auth_ref": [ "r34", "r35", "r178" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.", "label": "Common Stocks, Including Additional Paid in Capital", "terseLabel": "Common stock, par value $0.01: 3,200 shares authorized; 1,758 shares issued and 1,300 shares outstanding at December\u00a031, 2022 and 1,744 shares issued and 1,322 shares outstanding at December\u00a031, 2021 and capital surplus" } } }, "localname": "CommonStocksIncludingAdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred income tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]", "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred income tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r64", "r388", "r390", "r399", "r968", "r993" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to CVS Health" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r227", "r243", "r388", "r390", "r398", "r967", "r992" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r77", "r397", "r966", "r990" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r109", "r110", "r263", "r264", "r500", "r1081" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r109", "r110", "r263", "r264", "r500", "r1056", "r1081" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r109", "r110", "r263", "r264", "r500", "r1081", "r1375" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r109", "r110", "r263", "r264", "r500" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percent" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r107", "r109", "r110", "r111", "r263", "r265", "r1081" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r109", "r110", "r263", "r264", "r500", "r1081" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r232", "r234", "r236" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable Interest Entities" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r1291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of receivables and contract liabilities from contracts with customers" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r641", "r643", "r654" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": 4.0, "parentTag": "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Trade receivables (included in accounts receivable, net)", "verboseLabel": "Trade receivables" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r641", "r642", "r654" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "periodEndLabel": "Contract liabilities, end of period", "periodStartLabel": "Contract liabilities, beginning of period", "terseLabel": "Contract liabilities (included in accrued expenses)" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r1154", "r1292" ], "lang": { "en-us": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [ "r1154", "r1292" ], "lang": { "en-us": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateAndOtherMember": { "auth_ref": [ "r1242" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.", "label": "Corporate and Other [Member]", "terseLabel": "Corporate/ Other" } } }, "localname": "CorporateAndOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r121", "r486", "r487", "r488", "r489", "r495", "r1244" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate/ Other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r72", "r957" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r1294" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Products Sold" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r70" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Total operating costs", "totalLabel": "Total operating costs" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r1223", "r1331", "r1333" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r216", "r801", "r811", "r1223" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r1223", "r1331", "r1333" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r108", "r500" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelatedIntangibleAssetsMember": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships.", "label": "Customer-Related Intangible Assets [Member]", "terseLabel": "Customer contracts/relationships and covenants not to compete" } } }, "localname": "CustomerRelatedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r171", "r413", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r613", "r620", "r621", "r623" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Borrowings and Credit Agreements" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r27", "r28", "r29", "r278", "r280", "r300", "r421", "r597", "r598", "r599", "r600", "r601", "r603", "r609", "r610", "r611", "r612", "r614", "r615", "r616", "r617", "r618", "r619", "r885", "r1142", "r1143", "r1144", "r1145", "r1146", "r1221" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r29", "r280", "r300", "r624" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": { "order": 1.0, "parentTag": "cvs_LongtermDebtGrossAndLeaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Long-term debt", "totalLabel": "Subtotal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r269", "r271", "r597", "r885", "r1143", "r1144" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r611", "r863", "r1143", "r1144" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r47", "r598" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r48", "r421", "r597", "r598", "r599", "r600", "r601", "r603", "r609", "r610", "r611", "r612", "r614", "r615", "r616", "r617", "r618", "r619", "r885", "r1142", "r1143", "r1144", "r1145", "r1146", "r1221" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r48", "r174", "r175", "r176", "r177", "r268", "r269", "r271", "r295", "r421", "r597", "r598", "r599", "r600", "r601", "r603", "r609", "r610", "r611", "r612", "r614", "r615", "r616", "r617", "r618", "r619", "r622", "r885", "r1142", "r1143", "r1144", "r1145", "r1146", "r1221" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedPremium": { "auth_ref": [ "r268", "r271", "r1289" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt premium.", "label": "Debt Instrument, Unamortized Premium", "terseLabel": "Debt premiums" } } }, "localname": "DebtInstrumentUnamortizedPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r509", "r543", "r550", "r551" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "negatedTerseLabel": "Allowance for Credit Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "auth_ref": [ "r1250" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "totalLabel": "Net Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r520", "r548", "r1139" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Fair Value, Greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r520", "r548" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Unrealized Losses, Greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r1262" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Number of Securities, Greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r520", "r548", "r1139" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "verboseLabel": "Fair Value, Less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r520", "r548" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "verboseLabel": "Unrealized Losses, Less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r1262" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Number of Securities, Less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r521" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain", "terseLabel": "Gross realized capital gains" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r521" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Loss", "terseLabel": "Gross realized capital losses" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r1253" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of Debt Securities Available For Sale" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r517", "r544", "r1139" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "totalLabel": "Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r518", "r545" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "totalLabel": "Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r519", "r546" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "totalLabel": "Number of Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt securities" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r1223", "r1332", "r1333" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r93", "r216", "r802", "r810", "r811", "r1223" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r31", "r32", "r279", "r299", "r797" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred income tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r783", "r784" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r94" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredPolicyAcquisitionCostAmortizationExpense": { "auth_ref": [ "r980", "r995", "r1002", "r1003", "r1031", "r1175", "r1219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense (reversal of expense) for deferred policy acquisition costs.", "label": "Deferred Policy Acquisition Costs, Amortization Expense", "negatedTerseLabel": "Amortization expense" } } }, "localname": "DeferredPolicyAcquisitionCostAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDeferredAcquisitionCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredPolicyAcquisitionCosts": { "auth_ref": [ "r988", "r1003", "r1004", "r1031", "r1053", "r1175" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred policy acquisition cost capitalized on contract remaining in force.", "label": "Deferred Policy Acquisition Cost", "periodEndLabel": "Deferred acquisition costs, end of the period", "periodStartLabel": "Deferred acquisition costs, beginning of the period", "terseLabel": "Deferred acquisition costs" } } }, "localname": "DeferredPolicyAcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDeferredAcquisitionCostsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredPolicyAcquisitionCostsAdditions": { "auth_ref": [ "r1175", "r1363", "r1371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred policy acquisition cost capitalized.", "label": "Deferred Policy Acquisition Cost, Capitalization", "terseLabel": "Capitalizations" } } }, "localname": "DeferredPolicyAcquisitionCostsAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDeferredAcquisitionCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredPolicyAcquisitionCostsTableTextBlock": { "auth_ref": [ "r326", "r1005", "r1031", "r1175" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the movement in deferred policy acquisition costs.", "label": "Deferred Policy Acquisition Costs [Table Text Block]", "terseLabel": "Rollforward of deferred acquisition costs" } } }, "localname": "DeferredPolicyAcquisitionCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r1223", "r1332", "r1333" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r214", "r1330" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred income" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r214", "r1330" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInvestments": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 12.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).", "label": "Deferred Tax Assets, Investments", "terseLabel": "Investments" } } }, "localname": "DeferredTaxAssetsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r1329" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred income tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r214", "r1330" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss and capital loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r214", "r1330" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r214", "r1330" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation", "terseLabel": "Employee benefits" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": { "auth_ref": [ "r214", "r1330" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 11.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent", "terseLabel": "Lease and rents" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements": { "auth_ref": [ "r214", "r1330" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements", "terseLabel": "Legal charges" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": { "auth_ref": [ "r214", "r1330" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves", "terseLabel": "Insurance reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r798" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance", "verboseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r210", "r1329" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred income tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesInvestments": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).", "label": "Deferred Tax Liabilities, Investments", "negatedLabel": "Investments" } } }, "localname": "DeferredTaxLiabilitiesInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r214", "r1330" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedTerseLabel": "Lease and rents" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r672", "r1157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": { "auth_ref": [ "r686", "r1157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r665" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedTerseLabel": "Actuarial gain" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r658", "r697", "r719", "r1157", "r1158" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Amortization of net actuarial loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "auth_ref": [ "r186", "r189" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "totalLabel": "Net assets" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]", "terseLabel": "Assets (liabilities) recognized on the consolidated balance sheet" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r276", "r303", "r656", "r657", "r680", "r1157" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Noncurrent assets reflected in other assets" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r705", "r724" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "terseLabel": "Expected long-term rate of return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r660" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Benefit obligation, end of year", "periodStartLabel": "Benefit obligation, beginning of year", "terseLabel": "Benefit obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r667", "r727" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Benefit payments" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement": { "auth_ref": [ "r1295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement.", "label": "Defined Benefit Plan, Benefit Obligation, Payment for Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanBenefitObligationPaymentForSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r708", "r1155", "r1156", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "auth_ref": [ "r1155" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change in benefit obligation:" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in plan assets:" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember": { "auth_ref": [ "r1296" ], "lang": { "en-us": { "role": { "documentation": "Regulated trust, responsible for collective investment and reinvestment of asset from employee benefit plan maintained by more than one employer, in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Common Collective Trust [Member]", "verboseLabel": "Common/collective trusts" } } }, "localname": "DefinedBenefitPlanCommonCollectiveTrustMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r674", "r684", "r723", "r1155", "r1156", "r1157", "r1158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Employer contributions", "verboseLabel": "Employer contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": { "auth_ref": [ "r1155", "r1156", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]", "terseLabel": "International" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": { "auth_ref": [ "r1155", "r1156", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities, US [Member]", "terseLabel": "U.S. domestic" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r691" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "2028-2032" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r691" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r691" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2027" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r691" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2026" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r691" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r691" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r658", "r696", "r718", "r1157", "r1158" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r671", "r682", "r684", "r685", "r1155", "r1156", "r1157" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r656", "r680", "r1157" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "totalLabel": "Funded status" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r658", "r663", "r695", "r717", "r1157", "r1158" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r693", "r715", "r1157", "r1158" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "terseLabel": "Net periodic benefit cost", "totalLabel": "Net periodic benefit cost (income)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Components of net periodic benefit cost (income):" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r676", "r1298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Benefit payments" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock": { "auth_ref": [ "r1296", "r1297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of defined benefit plan asset investment. Includes, but is not limited to, fair value of category of plan asset and its level within fair value hierarchy.", "label": "Defined Benefit Plan, Plan Assets, Category [Table Text Block]", "terseLabel": "Schedule of Change in Level 3 Plan Assets" } } }, "localname": "DefinedBenefitPlanPlanAssetsCategoryTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount": { "auth_ref": [ "r1296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment within defined benefit plan asset category.", "label": "Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount", "terseLabel": "Plan assets, investment within plan asset category, amount" } } }, "localname": "DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r681", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Target investment allocations" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": { "auth_ref": [ "r687", "r1157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement", "verboseLabel": "Purchases, sales and settlements" } } }, "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRealEstateMember": { "auth_ref": [ "r1155", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Real Estate [Member]", "terseLabel": "Real estate" } } }, "localname": "DefinedBenefitPlanRealEstateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r659", "r700", "r722" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Settlement losses" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r679" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": { "auth_ref": [ "r688", "r1157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3", "terseLabel": "Transfers out of Level 3" } } }, "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "terseLabel": "Assumptions used to determine benefit obligations" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "terseLabel": "Assumptions used to determine net benefit costs" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r193", "r194", "r195", "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Defined contribution plan, employer contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r93", "r155" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r93", "r470" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r249", "r250", "r252", "r253", "r1128" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r1335", "r1336" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Forward contract, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r244", "r245", "r246", "r247", "r254", "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DirectPremiumsEarned": { "auth_ref": [ "r317", "r997", "r1041", "r1044" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 1.0, "parentTag": "us-gaap_PremiumsEarnedNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums earned.", "label": "Direct Premiums Earned", "terseLabel": "Direct" } } }, "localname": "DirectPremiumsEarned", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r653", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r1292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r738", "r769", "r770", "r772", "r777", "r1166" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Disclosure of Long-Lived Assets Held-for-sale [Table Text Block]", "terseLabel": "Summary of Assets and Liabilities Held for Sale" } } }, "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r14", "r68", "r319" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Loss from discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Loss from discontinued operations attributable to CVS Health (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Loss from discontinued operations attributable to CVS Health (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r4", "r5", "r6", "r7", "r14", "r17", "r785", "r809", "r815" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "negatedTerseLabel": "Income tax benefit" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale" } } }, "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "auth_ref": [ "r8", "r21" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.", "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DiscontinuedOperationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails", "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails", "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r153", "r160" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r151", "r160", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails", "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r0", "r1", "r15", "r159" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivable, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "auth_ref": [ "r0", "r1", "r15", "r159" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "auth_ref": [ "r0", "r1", "r15", "r159" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": { "auth_ref": [ "r0", "r1", "r15", "r159" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets", "terseLabel": "Deferred income taxes" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r0", "r1", "r15", "r159" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "auth_ref": [ "r0", "r1", "r15", "r159" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Other" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r0", "r1", "r15", "r159" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Other" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r0", "r1", "r15", "r159" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r1159", "r1162" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r178", "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "negatedTerseLabel": "Common stock dividends" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Cash dividend declared (USD per share)" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DividendsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Dividends Payable [Line Items]", "terseLabel": "Dividends Payable [Line Items]" } } }, "localname": "DividendsPayableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableTable": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.", "label": "Dividends Payable [Table]", "terseLabel": "Dividends Payable [Table]" } } }, "localname": "DividendsPayableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "auth_ref": [ "r125", "r1157", "r1296" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation domiciled in United States of America (US).", "label": "Debt Security, Corporate, US [Member]", "terseLabel": "U.S. corporate securities" } } }, "localname": "DomesticCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per share attributable to CVS Health:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r400", "r431", "r432", "r434", "r435", "r436", "r442", "r444", "r449", "r450", "r451", "r455", "r845", "r846", "r969", "r994", "r1133" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income attributable to CVS Health (in dollars per share)", "totalLabel": "Net income attributable to CVS Health (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "verboseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r400", "r431", "r432", "r434", "r435", "r436", "r444", "r449", "r450", "r451", "r455", "r845", "r846", "r969", "r994", "r1133" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income attributable to CVS Health (in dollars per share)", "totalLabel": "Net income attributable to CVS Health (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r452", "r453", "r454", "r456" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r786" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r416", "r786", "r812" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": { "auth_ref": [ "r1327", "r1334" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.", "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent", "terseLabel": "Basis difference upon disposition of subsidiary" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r1327", "r1334" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r1327", "r1334" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income taxes, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic": { "auth_ref": [ "r1327", "r1334" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to domestic income tax settlement.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Domestic, Percent", "terseLabel": "Prior year refunds and unrecognized tax benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectsOfReinsuranceTableTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.", "label": "Effects of Reinsurance [Table Text Block]", "terseLabel": "Schedule of Impact of Reinsurance on Benefit Costs" } } }, "localname": "EffectsOfReinsuranceTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r771" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Compensation not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r1326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Compensation not yet recognized, other than options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r1326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Compensation not yet recognized, options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r173", "r355", "r392", "r393", "r394", "r423", "r424", "r425", "r428", "r437", "r440", "r458", "r531", "r640", "r773", "r774", "r775", "r806", "r807", "r844", "r873", "r874", "r875", "r876", "r877", "r879", "r919", "r1028", "r1029", "r1030" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r87", "r137", "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r372", "r861", "r1125" ], "calculation": { "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r136", "r301", "r1194", "r1195", "r1196" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r523" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r611", "r863", "r1143", "r1144" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimated Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "verboseLabel": "Aggregate principal of debt extinguished" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci": { "auth_ref": [ "r856" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), OCI", "negatedTerseLabel": "Change in unrealized capital losses included in OCI associated with Level 3 financial assets" } } }, "localname": "FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r849", "r850", "r859" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r257", "r259" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Changes in Level 3 Financial Assets" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r256", "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r256", "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of Carrying Value and Fair Value By Level of Fair Value Hierarchy" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r611", "r684", "r685", "r686", "r687", "r688", "r689", "r850", "r925", "r926", "r927", "r1143", "r1144", "r1155", "r1156", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r256", "r260", "r611", "r1143", "r1144" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r849", "r850", "r851", "r852", "r860" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r611", "r1143", "r1144" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r858" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel12And3Member": { "auth_ref": [ "r1297" ], "lang": { "en-us": { "role": { "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).", "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]", "terseLabel": "Total Fair Value, Inputs, Level 1, 2 and 3" } } }, "localname": "FairValueInputsLevel12And3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r611", "r684", "r689", "r850", "r925", "r1155", "r1156", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r611", "r684", "r689", "r850", "r926", "r1143", "r1144", "r1155", "r1156", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r611", "r684", "r685", "r686", "r687", "r688", "r689", "r850", "r927", "r1143", "r1144", "r1155", "r1156", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [ "r684", "r848", "r860" ], "lang": { "en-us": { "role": { "documentation": "Fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "Fair Value Measured at Net Asset Value Per Share" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r853" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Included in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "auth_ref": [ "r854" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "terseLabel": "Included in other comprehensive income (loss)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "auth_ref": [ "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "negatedTerseLabel": "Sales" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "auth_ref": [ "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "negatedTerseLabel": "Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r855" ], "calculation": { "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details": { "order": 1.0, "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Gross transfers into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "terseLabel": "Transfers into (out of) Level 3, net", "totalLabel": "Net transfers into (out of) Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r855" ], "calculation": { "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details": { "order": 2.0, "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "negatedTerseLabel": "Gross transfers out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r611", "r684", "r685", "r686", "r687", "r688", "r689", "r925", "r926", "r927", "r1143", "r1144", "r1155", "r1156", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r849", "r850", "r851", "r852", "r857", "r860" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Nonrecurring" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r858", "r860" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable": { "auth_ref": [ "r46", "r285", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum advances or credit lines available from the Federal Home Loan Bank (FHLB).", "label": "Federal Home Loan Bank, Advances, General Debt Obligations, Maximum Amount Available", "terseLabel": "Federal home loan bank advances maximum amount available" } } }, "localname": "FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalHomeLoanBankAdvancesMember": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans.", "label": "Federal Home Loan Bank Advances [Member]", "terseLabel": "Federal Home Loan Bank Advances" } } }, "localname": "FederalHomeLoanBankAdvancesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r893", "r899", "r1172" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 1.0, "parentTag": "cvs_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r895", "r905" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows paid for interest portion of finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r891", "r910" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": { "order": 2.0, "parentTag": "cvs_LongtermDebtGrossAndLeaseObligation", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total finance lease liabilities", "totalLabel": "Total finance lease liabilities", "verboseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails", "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r891" ], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of long-term debt" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r1347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Maturities of Finance Lease Liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r891" ], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term debt" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueAfterYearFive", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsYearOne", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearFive", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearFour", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearThree", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearTwo", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r892" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease liability.", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r894", "r905" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows paid for principal portion of finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r893", "r899", "r1172" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 2.0, "parentTag": "cvs_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r908", "r1172" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r907", "r1172" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r515", "r516", "r535", "r539", "r540", "r541", "r542", "r547", "r549", "r552", "r622", "r638", "r834", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r1139", "r1254", "r1255", "r1256", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "terseLabel": "Assets:" } } }, "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Financial liabilities measured at fair value on a recurring basis" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension", "terseLabel": "Weighted Average Life (years)" } } }, "localname": "FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r369", "r572" ], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r570", "r571", "r572", "r573", "r958", "r962" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r145", "r962" ], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-lived intangible assets, gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r141", "r144" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r145", "r958" ], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": 1.0, "parentTag": "cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Finite-lived intangible assets, net carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCorporateDebtSecuritiesMember": { "auth_ref": [ "r125", "r1296" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation not domiciled in United States of America (US).", "label": "Debt Security, Corporate, Non-US [Member]", "terseLabel": "Foreign securities" } } }, "localname": "ForeignCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r881" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term debt securities issued by a national, local, or municipal government not within the country of domicile of the reporting entity.", "label": "Foreign Government Short-Term Debt Securities [Member]", "terseLabel": "Foreign securities" } } }, "localname": "ForeignGovernmentShorttermDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r1337" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Fixtures and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingencyUnrecordedAmount": { "auth_ref": [ "r1281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.", "label": "Gain Contingency, Unrecorded Amount", "terseLabel": "Gain contingency, unrecorded amount" } } }, "localname": "GainContingencyUnrecordedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r830", "r1219" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedLabel": "Gain on divestiture of subsidiaries", "negatedTerseLabel": "Gain on sale of subsidiaries", "terseLabel": "Gain (loss) on sale of subsidiaries" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r1276" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Opioid litigation charges" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r93", "r169", "r170" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on early extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r169", "r170" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.", "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost", "negatedTerseLabel": "Premium paid in excess of debt principal" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r368", "r556", "r963", "r1140", "r1173", "r1263", "r1270" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance, end of the period", "periodStartLabel": "Balance, beginning of the period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "Goodwill and Other Intangibles" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangibles" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r568", "r569", "r1140" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r558", "r565", "r1140" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Cumulative goodwill impairments" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r93", "r557", "r562", "r568", "r1140" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Impairment", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r561", "r1140" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Divestitures" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsMaximumExposure": { "auth_ref": [ "r165" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.", "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "terseLabel": "Guarantor obligations, maximum exposure" } } }, "localname": "GuaranteeObligationsMaximumExposure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCareCostsPolicyPolicyTextBlock": { "auth_ref": [ "r1082", "r1084" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accruing health care costs for a prepaid health care service provider.", "label": "Health Care Costs, Policy [Policy Text Block]", "terseLabel": "Health Care Costs Payable" } } }, "localname": "HealthCareCostsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_HealthCareEntitiesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for all health care policies.", "label": "Health Care Entities, Policy [Policy Text Block]", "terseLabel": "Health Care Reform" } } }, "localname": "HealthCareEntitiesPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_HealthInsuranceProductLineMember": { "auth_ref": [ "r1370" ], "lang": { "en-us": { "role": { "documentation": "Product line consisting of insurance against loss by illness or injury.", "label": "Health Insurance Product Line [Member]", "terseLabel": "Health Insurance Product Line" } } }, "localname": "HealthInsuranceProductLineMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgeFundsMember": { "auth_ref": [ "r1296" ], "lang": { "en-us": { "role": { "documentation": "Investments in registered hedge funds.", "label": "Hedge Funds [Member]", "verboseLabel": "Hedge fund investments" } } }, "localname": "HedgeFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r1219", "r1274" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets, indefinite-lived" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r93", "r152" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Loss on assets held for sale" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Recoverability of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r71", "r94", "r226", "r431", "r432", "r434", "r435", "r448", "r451" ], "calculation": { "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Income from continuing operations attributable to CVS Health" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r67", "r273", "r288", "r322", "r475", "r486", "r492", "r495", "r971", "r1135" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income tax provision", "totalLabel": "Income before income tax provision" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r227", "r415", "r427", "r475", "r486", "r492", "r495", "r526", "r584", "r585", "r587", "r588", "r589", "r591", "r593", "r595", "r596", "r846", "r864", "r1135", "r1284" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Income from continuing operations", "totalLabel": "Income from continuing operations", "verboseLabel": "Income from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r66", "r287", "r289", "r318", "r400", "r427", "r431", "r432", "r434", "r435", "r444", "r449", "r450", "r846", "r969" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Income from continuing operations attributable to CVS Health (in dollars per share)", "verboseLabel": "Earnings per share from continuing operations, basic (USD per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r66", "r318", "r321", "r400", "r427", "r431", "r432", "r434", "r435", "r444", "r449", "r450", "r451", "r846", "r969", "r994" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Income from continuing operations attributable to CVS Health (in dollars per share)", "verboseLabel": "Earnings per share from continuing operations, diluted (USD per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r17", "r319", "r360", "r816" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Loss from discontinued operations, net of tax", "totalLabel": "Loss from discontinued operations, net of tax" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r1159", "r1162" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r416", "r787", "r795", "r800", "r808", "r813", "r817", "r818", "r819" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r417", "r439", "r440", "r473", "r785", "r809", "r814", "r996" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 }, "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Total", "verboseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r391", "r781", "r782", "r795", "r796", "r799", "r803" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r97" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r92" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable and pharmacy claims and discounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r92" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInsuranceLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in insurance liability balances during the period.", "label": "Increase (Decrease) in Insurance Liabilities", "terseLabel": "Health care costs payable and other insurance liabilities" } } }, "localname": "IncreaseDecreaseInInsuranceLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r92" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r92" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r445", "r446", "r447", "r451", "r737" ], "calculation": { "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Effect of dilutive securities (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r148" ], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": 2.0, "parentTag": "cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets, Trademarks" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Insurance [Abstract]", "terseLabel": "Insurance [Abstract]" } } }, "localname": "InsuranceAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InsuranceContractAcquisitionCostTextBlock": { "auth_ref": [ "r1006" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cost related directly to successful acquisition of new and renewal of insurance contract. Includes, but is not limited to, deferred policy acquisition cost, deferred sale inducement cost, and present value of future profit of insurance contract acquired in business combination.", "label": "Insurance Contract, Acquisition Cost [Text Block]", "terseLabel": "Other Insurance Liabilities and Separate Accounts" } } }, "localname": "InsuranceContractAcquisitionCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccounts" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r368" ], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Intangible assets, gross" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r139", "r143" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCreditedToPolicyholdersAccountBalances": { "auth_ref": [ "r979", "r1186", "r1188", "r1362", "r1367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense for allocation to policyholder account balance.", "label": "Policyholder Account Balance, Interest Expense", "terseLabel": "Interest credited" } } }, "localname": "InterestCreditedToPolicyholdersAccountBalances", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r270", "r291", "r395", "r469", "r884" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r406", "r411", "r412" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Amount expected to be reclassified" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalCreditAssessmentAxis": { "auth_ref": [ "r122", "r833", "r1137", "r1138", "r1141", "r1260" ], "lang": { "en-us": { "role": { "documentation": "Information by entity-defined rating.", "label": "Internal Credit Assessment [Axis]", "terseLabel": "Internal Credit Assessment [Axis]" } } }, "localname": "InternalCreditAssessmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InternalCreditAssessmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity defined credit risk rating.", "label": "Internal Credit Assessment [Domain]", "terseLabel": "Internal Credit Assessment [Domain]" } } }, "localname": "InternalCreditAssessmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r467", "r485", "r486", "r487", "r488", "r489", "r491", "r495" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment Eliminations" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r376", "r1124", "r1173" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r363", "r375", "r457", "r553", "r554", "r555", "r956", "r1130" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r74" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": 1.0, "parentTag": "cvs_InvestmentIncomeExcludingCapitalGainsOrLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Gross investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInvestmentExpense": { "auth_ref": [ "r76", "r323" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": 2.0, "parentTag": "cvs_InvestmentIncomeExcludingCapitalGainsOrLosses", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the generation of investment income.", "label": "Investment Income, Investment Expense", "negatedLabel": "Investment expenses" } } }, "localname": "InvestmentIncomeInvestmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r74", "r75" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "totalLabel": "Net investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeTextBlock": { "auth_ref": [ "r74", "r75", "r76", "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table Text Block]", "verboseLabel": "Schedule of Net Investment Income" } } }, "localname": "InvestmentIncomeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r525", "r1361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Investments": { "auth_ref": [ "r314" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "totalLabel": "Total" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]", "terseLabel": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Schedule of Amortized Cost and Fair Value of Debt Securities by Contractual Maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r136", "r274", "r292", "r348", "r1099" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r1293" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r909", "r1172" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Net lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Finance lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r1346" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of the Components of Net Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Attorneys' fees and costs" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r1345" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Finance lease term (in years)" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r911" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r898" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r897" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Right-of-Use Assets and Lease Liabilities" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r1347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueAfterYearFive", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsYearOne", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearFive", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearFour", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearThree", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearTwo", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r910" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r1345" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term (in years)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r911" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r912" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "terseLabel": "Future noncancelable subleases, future minimum payments" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r415", "r526", "r584", "r585", "r587", "r588", "r589", "r591", "r593", "r595", "r596", "r826", "r831", "r832", "r864", "r1134", "r1284", "r1350", "r1351" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r39", "r282", "r309", "r1173", "r1222", "r1257", "r1342" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r362", "r415", "r526", "r584", "r585", "r587", "r588", "r589", "r591", "r593", "r595", "r596", "r826", "r831", "r832", "r864", "r1173", "r1284", "r1350", "r1351" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "terseLabel": "Total current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r15", "r159", "r359", "r360" ], "calculation": { "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r15", "r154", "r159", "r359", "r360" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r327", "r330" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "weight": 1.0 }, "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.", "label": "Liability for Claims and Claims Adjustment Expense", "periodEndLabel": "Health care costs payable, end of period", "periodStartLabel": "Health care costs payable, beginning of period", "terseLabel": "Health care costs payable", "totalLabel": "Total health care costs payable", "verboseLabel": "Health care costs payable" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitActivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Future Policy Benefit, Activity [Line Items]", "terseLabel": "Liability for Future Policy Benefit, Activity [Line Items]" } } }, "localname": "LiabilityForFuturePolicyBenefitActivityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsUndiscountedExpectedGrossPremiumsandExpectedFutureBenefitPaymentsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitActivityTable": { "auth_ref": [ "r1013", "r1187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about activity for liability for future policy benefit. Includes, but is not limited to, beginning and ending balance, issuance, interest income (expense), net premium collected, benefit payment, derecognition, experience adjustment, change in cash flow assumption, and change in discount rate assumption.", "label": "Liability for Future Policy Benefit Activity [Table]", "terseLabel": "Liability for Future Policy Benefit Activity [Table]" } } }, "localname": "LiabilityForFuturePolicyBenefitActivityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsUndiscountedExpectedGrossPremiumsandExpectedFutureBenefitPaymentsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock": { "auth_ref": [ "r1013", "r1031", "r1187" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of beginning balance to ending balance for liability for future policy benefit, with separate presentation of expected future net premium and expected future benefit.", "label": "Liability for Future Policy Benefit, Activity [Table Text Block]", "terseLabel": "Schedule of Changes in Liability for Future Policy Benefits" } } }, "localname": "LiabilityForFuturePolicyBenefitActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitAfterReinsurance": { "auth_ref": [ "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effect of reinsurance, of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, after Reinsurance", "periodEndLabel": "Adjusted balance at January 1, 2021, net of reinsurance", "terseLabel": "Liability for future policy benefits", "totalLabel": "Net liability for future policy benefits, net of reinsurance recoverable" } } }, "localname": "LiabilityForFuturePolicyBenefitAfterReinsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate": { "auth_ref": [ "r1018", "r1187" ], "lang": { "en-us": { "role": { "documentation": "Current weighted-average discount rate used to measure liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Current Weighted-Average Discount Rate", "terseLabel": "Current discount rate" } } }, "localname": "LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange": { "auth_ref": [ "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption, of expected future benefit and expense component for liability for future policy benefit, discounted at original rate.", "label": "Liability for Future Policy Benefit, Expected Future Benefit, Original Discount Rate, before Reinsurance, after Cash Flow Change", "totalLabel": "Adjusted beginning liability for future policy benefits - original (locked-in) discount rate" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance": { "auth_ref": [ "r1014", "r1187" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance, of undiscounted balance for expected future gross premium component of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Expected Future Gross Premium, Undiscounted, before Reinsurance", "terseLabel": "Expected gross premiums" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsUndiscountedExpectedGrossPremiumsandExpectedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange": { "auth_ref": [ "r1013", "r1014", "r1031", "r1187" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefits", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption and discount rate change, of expected future policy benefit and expense component of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, before Reinsurance, after Discount Rate Change", "periodEndLabel": "Liability for future policy benefits, end of period - current discount rate", "periodStartLabel": "Liability for future policy benefits, beginning of period - current discount rate" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChange": { "auth_ref": [ "r1182", "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in expected future policy benefit and expense component for liability of future policy benefit from cash flow assumption change for future cash flows.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) from Cash Flow Change", "terseLabel": "Effect of changes in cash flow assumptions" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChange", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience": { "auth_ref": [ "r1015", "r1181", "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in expected future policy benefit and expense component for liability of future policy benefit from effect of variance from cash flow assumption change for actual experience.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) of Actual Variance from Expected Experience", "terseLabel": "Effect of actual variances from expected experience" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpense": { "auth_ref": [ "r1178", "r1187", "r1366", "r1371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense for expected future policy benefit and expense component of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Interest Expense", "terseLabel": "Interest accrual (using locked-in discount rate)" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuance": { "auth_ref": [ "r1177", "r1187", "r1366", "r1371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in expected future policy benefit and expense component of liability for future policy benefit from contract issuance.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Issuance", "terseLabel": "Issuances" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance": { "auth_ref": [ "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance and current period update of cash flow assumption, of expected future policy benefit and expense component of liability for future policy benefit, discounted at original rate.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance", "periodEndLabel": "Ending liability for future policy benefits at original (locked-in) discount rate", "periodStartLabel": "Beginning liability for future policy benefits at original (locked-in) discount rate" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]", "terseLabel": "Present value of expected future policy benefits" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance": { "auth_ref": [ "r1014", "r1187" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance, of undiscounted balance for expected future policy benefit and expense component of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Undiscounted, before Reinsurance", "terseLabel": "Expected future benefit payments" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsUndiscountedExpectedGrossPremiumsandExpectedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange": { "auth_ref": [ "r1013", "r1014", "r1031", "r1187" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefits", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption and discount rate change, of expected net premium component of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Expected Net Premium, before Reinsurance, after Discount Rate Change", "periodEndLabel": "Liability for future policy benefits, end of period - current discount rate", "periodStartLabel": "Liability for future policy benefits, beginning of period - current discount rate" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChange": { "auth_ref": [ "r1182", "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in expected net premium component of liability for future policy benefit from cash flow assumption change for future cash flows.", "label": "Liability for Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) from Cash Flow Change", "terseLabel": "Effect of changes in cash flow assumptions" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChange", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience": { "auth_ref": [ "r1015", "r1181", "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in expected net premium component for liability of future policy benefit from effect of variance from cash flow assumption change for actual experience.", "label": "Liability for Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) of Actual Variance from Expected Experience", "terseLabel": "Effect of actual variances from expected experience" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncome": { "auth_ref": [ "r1178", "r1187", "r1366", "r1371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income for expected net premium component of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Expected Net Premium, Interest Income", "terseLabel": "Interest accrual (using locked-in discount rate)" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected": { "auth_ref": [ "r1179", "r1187", "r1366", "r1371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of premium collected from policyholder to fund expected benefit payment for expected net premium component of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Expected Net Premium, Net Premium Collected", "negatedTerseLabel": "Net premiums (actual)" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance": { "auth_ref": [ "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance and current period update of cash flow assumption, of expected net premium component of liability for future policy benefit, discounted at original rate.", "label": "Liability for Future Policy Benefit, Expected Net Premium, Original Discount Rate, before Cash Flow and Reinsurance", "periodEndLabel": "Ending liability for future policy benefits at original (locked-in) discount rate", "periodStartLabel": "Beginning liability for future policy benefits at original (locked-in) discount rate" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange": { "auth_ref": [ "r1187", "r1366", "r1371" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption, of expected net premium component for liability for future policy benefit, discounted at original rate.", "label": "Liability for Future Policy Benefit, Expected Net Premium, Original Discount Rate, before Reinsurance, after Cash Flow Change", "totalLabel": "Adjusted beginning liability for future policy benefits - original (locked-in) discount rate" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]", "terseLabel": "Present value of expected net premiums" } } }, "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance": { "auth_ref": [ "r1013", "r1016", "r1031", "r1187" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitAfterReinsurance", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, recoverable under reinsurance of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Reinsurance Recoverable, after Allowance", "periodEndLabel": "Less: Reinsurance recoverable", "terseLabel": "Less: Reinsurance recoverable", "verboseLabel": "Add: Reinsurance recoverable" } } }, "localname": "LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration": { "auth_ref": [ "r1017" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average duration of liability for future policy benefit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Liability for Future Policy Benefit, Weighted-Average Duration", "terseLabel": "Weighted-average duration of long-duration insurance liabilities" } } }, "localname": "LiabilityForFuturePolicyBenefitWeightedAverageDuration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate": { "auth_ref": [ "r1018", "r1187" ], "lang": { "en-us": { "role": { "documentation": "Original weighted-average discount rate at contract issue date used to measure liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Weighted-Average Interest Accretion Rate", "terseLabel": "Interest accretion rate" } } }, "localname": "LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsWeightedaverageInterestRatesandDurationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LiabilityForFuturePolicyBenefits": { "auth_ref": [ "r984", "r1013", "r1019", "r1031", "r1187" ], "calculation": { "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitAfterReinsurance", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.", "label": "Liability for Future Policy Benefit, before Reinsurance", "totalLabel": "Net liability for future policy benefits", "verboseLabel": "Liability for future policy benefits" } } }, "localname": "LiabilityForFuturePolicyBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": { "auth_ref": [ "r1038" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.", "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]", "terseLabel": "Health Care Costs Payable" } } }, "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits": { "auth_ref": [ "r1180", "r1187", "r1218", "r1366", "r1371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to policyholder from benefit payment for expected future policy benefit and expense component of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment", "negatedTerseLabel": "Benefit payments (actual)" } } }, "localname": "LiabilityForFuturePolicyBenefitsPaymentForBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinLiabilityforFuturePolicyBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions", "verboseLabel": "Acquisitions, net" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]", "terseLabel": "Less: Claims paid" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "auth_ref": [ "r329" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "terseLabel": "Current year" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "auth_ref": [ "r329" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "terseLabel": "Prior years" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "auth_ref": [ "r328" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "totalLabel": "Total incurred health care costs" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]", "terseLabel": "Add: Components of incurred health care costs" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": { "auth_ref": [ "r298", "r327", "r330" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net", "periodEndLabel": "Health care costs payable, end of period, net", "periodStartLabel": "Health care costs payable, beginning of period, net" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Amount awarded from other party" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Legal settlement awarded to other party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r1276" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r1276" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r29" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-Term Debt and Lease Obligation", "terseLabel": "Long-term debt (1)" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-Term Debt and Lease Obligation, Current", "negatedTerseLabel": "Current portion of long-term debt", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails", "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.", "label": "Long-Term Debt and Lease Obligation, Including Current Maturities", "totalLabel": "Long-term debt and lease obligation" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r167", "r421", "r1290" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r167", "r421", "r615" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r167", "r421", "r615" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r167", "r421", "r615" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r167", "r421", "r615" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r167", "r421", "r615" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r365" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-Term Investments", "verboseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r48", "r168" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r163", "r164", "r579", "r580", "r581", "r1277", "r1278" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r579", "r1204" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Liability recorded in association with legal settlement" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": { "auth_ref": [ "r579" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Noncurrent", "terseLabel": "Long-term liability recorded in association with legal settlement" } } }, "localname": "LossContingencyAccrualCarryingValueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r1277", "r1278" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Number of claims" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r22", "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "verboseLabel": "Acquisitions, Divestitures and Asset Sales" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSales" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r55", "r281", "r308", "r415", "r526", "r584", "r587", "r588", "r589", "r595", "r596", "r864" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageLoansOnRealEstate": { "auth_ref": [ "r1074" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate", "terseLabel": "Mortgage loans" } } }, "localname": "MortgageLoansOnRealEstate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet": { "auth_ref": [ "r313" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The balance represents the amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio.", "label": "Mortgage Loans on Real Estate, Commercial and Consumer, Net", "totalLabel": "Total" } } }, "localname": "MortgageLoansOnRealEstateCommercialAndConsumerNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageLoansOnRealEstateForeclosures": { "auth_ref": [ "r1076" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from foreclosure.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Foreclosure", "terseLabel": "Mortgage loans foreclosed" } } }, "localname": "MortgageLoansOnRealEstateForeclosures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageLoansOnRealEstateNewMortgageLoans": { "auth_ref": [ "r1076" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from new investment.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, New Mortgage Loan", "terseLabel": "New mortgage loans" } } }, "localname": "MortgageLoansOnRealEstateNewMortgageLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgagesHeldForSaleFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of mortgage loans held-for-sale.", "label": "Mortgages Held-for-sale, Fair Value Disclosure", "terseLabel": "Mortgage loans" } } }, "localname": "MortgagesHeldForSaleFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementAnalysisOfDeferredPolicyAcquisitionCostsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]", "terseLabel": "Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]" } } }, "localname": "MovementAnalysisOfDeferredPolicyAcquisitionCostsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDeferredAcquisitionCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MultiemployerPlanPensionInsignificantPlanContribution": { "auth_ref": [ "r1299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by multiemployer pension plan from all employers participating in multiemployer pension plan determined to be individually insignificant.", "label": "Multiemployer Plan, Pension, Insignificant, Plan Contribution", "terseLabel": "Multiemployer plans, plan contributions" } } }, "localname": "MultiemployerPlanPensionInsignificantPlanContribution", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r408" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r408" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r88", "r91", "r94" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Reconciliation of net income to net cash provided by operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r69", "r94", "r290", "r320", "r360", "r386", "r389", "r394", "r415", "r427", "r431", "r432", "r434", "r435", "r439", "r440", "r448", "r475", "r486", "r492", "r495", "r526", "r584", "r585", "r587", "r588", "r589", "r591", "r593", "r595", "r596", "r846", "r864", "r1135", "r1284" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income attributable to CVS Health", "totalLabel": "Net income attributable to CVS Health" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r229", "r242", "r386", "r389", "r439", "r440", "r1211" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net (income) loss attributable to noncontrolling interests", "negatedTerseLabel": "Comprehensive (income) loss attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentIncome": { "auth_ref": [ "r991" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.", "label": "Net Investment Income", "terseLabel": "Net investment income", "verboseLabel": "Net investment income (loss)" } } }, "localname": "NetInvestmentIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "verboseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r101", "r353", "r354", "r355", "r356", "r357", "r426", "r427", "r428", "r429", "r430", "r434", "r441", "r455", "r505", "r506", "r528", "r529", "r530", "r531", "r532", "r533", "r773", "r774", "r775", "r804", "r805", "r806", "r807", "r821", "r822", "r823", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r882", "r883", "r886", "r887", "r888", "r889", "r914", "r915", "r916", "r917", "r918", "r919", "r959", "r960", "r961", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "verboseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r224", "r640", "r1225", "r1226", "r1227" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r1243" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r1243" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states in which entity operates" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStores": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of stores.", "label": "Number of Stores", "terseLabel": "Number of retail locations (more than)" } } }, "localname": "NumberOfStores", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax": { "auth_ref": [ "r383", "r384" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of unrealized gain (loss) from (increase) decrease in liability for future policy benefit from change in discount rate.", "label": "OCI, Liability for Future Policy Benefit, Gain (Loss), after Reclassification Adjustment and Tax", "terseLabel": "Change in discount rate on insurance reserves" } } }, "localname": "OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating costs:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r475", "r486", "r492", "r495", "r1135" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "netLabel": "Operating income (GAAP measure)", "totalLabel": "Operating income", "verboseLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r900", "r1172" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r891" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LeaseLiability", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r891" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r891" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r896", "r905" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r890" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r908", "r1172" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r907", "r1172" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r495" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r377", "r1173" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r370" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r227", "r228", "r230" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Net unrealized investment gains (losses)" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r63", "r393", "r873", "r875", "r879", "r1209" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "OCI before reclassifications, pre-tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r63", "r65", "r393", "r873", "r875", "r879", "r1209" ], "calculation": { "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "negatedTerseLabel": "Loss on net cash flow hedges", "verboseLabel": "Other comprehensive income (loss) before reclassifications, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r379", "r384" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Net cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r56" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r65", "r173", "r387", "r390", "r397", "r873", "r878", "r879", "r966", "r990", "r1209", "r1210" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r59", "r61" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedTerseLabel": "Pension and other postretirement benefits" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r1252", "r1261", "r1296", "r1341" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other Debt Obligations" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other investments" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r94" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other noncash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPolicyholderFunds": { "auth_ref": [ "r315" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount due to policyholders for funds held that are returnable under the terms of insurance contracts, classified as other.", "label": "Other Policyholder Funds", "terseLabel": "Policyholders\u2019 funds" } } }, "localname": "OtherPolicyholderFunds", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r185", "r656", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r704", "r705", "r706", "r708", "r711", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r728", "r729", "r730", "r1157", "r1158", "r1159", "r1160", "r1161" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefits" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": 2.0, "parentTag": "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total CVS Health Shareholders\u2019 Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": { "auth_ref": [ "r404", "r1129" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.", "label": "Payments for Derivative Instrument, Financing Activities", "negatedTerseLabel": "Derivative settlements", "terseLabel": "Payments for derivative instruments" } } }, "localname": "PaymentsForDerivativeInstrumentFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Payments for Legal Settlements", "terseLabel": "Cash impact of litigation settlement" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "auth_ref": [ "r90", "r329" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "totalLabel": "Total claims paid" } } }, "localname": "PaymentsForLossesAndLossAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r1212", "r1213" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r85" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r85" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r403" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Payments for taxes related to net share settlement of equity awards", "terseLabel": "Payments for taxes for net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r80" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions (net of cash acquired)" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r82" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r81" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r410", "r1216", "r1217" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedTerseLabel": "Cash paid to other suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r1276" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r681", "r683", "r689", "r707", "r709", "r710", "r711", "r712", "r713", "r725", "r726", "r728", "r734", "r1157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "verboseLabel": "Pension Plans and Other Postretirement Benefits" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r28", "r656", "r657", "r680", "r1157" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedTerseLabel": "Current liabilities reflected in accrued expenses" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r30", "r656", "r657", "r680", "r1157" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedTerseLabel": "Noncurrent liabilities reflected in other long-term liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r193", "r198", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r184", "r656", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r704", "r705", "r706", "r708", "r711", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r728", "r729", "r733", "r1157", "r1158", "r1162", "r1163", "r1164" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plan" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r708", "r1155", "r1156", "r1157" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange": { "auth_ref": [ "r1188", "r1367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in liability for policyholder account balance from change, classified as other.", "label": "Policyholder Account Balance, Increase (Decrease) from Other Change", "terseLabel": "Other" } } }, "localname": "PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderAccountBalanceNetAmountAtRisk": { "auth_ref": [ "r1022", "r1188" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of guaranteed benefit in excess of current account balance of policyholder account balance.", "label": "Policyholder Account Balance, Net Amount at Risk", "terseLabel": "Net amount at risk" } } }, "localname": "PolicyholderAccountBalanceNetAmountAtRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderAccountBalancePolicyCharge": { "auth_ref": [ "r1184", "r1188", "r1367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in liability for policyholder account balance from policy charge.", "label": "Policyholder Account Balance, Policy Charge", "negatedTerseLabel": "Policy charges" } } }, "localname": "PolicyholderAccountBalancePolicyCharge", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderAccountBalanceRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Policyholder Account Balance [Roll Forward]", "terseLabel": "Policyholder Account Balance [Roll Forward]" } } }, "localname": "PolicyholderAccountBalanceRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PolicyholderAccountBalanceSurrenderAndWithdrawal": { "auth_ref": [ "r1188", "r1367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in liability for policyholder account balance from contract redemption and withdrawal of funds.", "label": "Policyholder Account Balance, Surrender and Withdrawal", "negatedTerseLabel": "Surrenders and withdrawals" } } }, "localname": "PolicyholderAccountBalanceSurrenderAndWithdrawal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderAccountBalanceTableTextBlock": { "auth_ref": [ "r1188", "r1368" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about policyholder account balance, including, but not limited to change in liability and related cash surrender value.", "label": "Policyholder Account Balance [Table Text Block]", "terseLabel": "Roll Forward of Policyholders' Funds" } } }, "localname": "PolicyholderAccountBalanceTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate": { "auth_ref": [ "r1021", "r1188" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average crediting rate for liability for policyholder account balance, calculated at a point in time.", "label": "Policyholder Account Balance, Weighted Average Crediting Rate", "terseLabel": "Weighted average crediting rate" } } }, "localname": "PolicyholderAccountBalanceWeightedAverageCreditingRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PolicyholderAccountsPolicy": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for contracts reported in separate accounts, including the extent and terms of minimum guarantees, basis of presentation for separate account assets and liabilities and related separate account activity, the liability valuation method and assumptions used in valuing each type of policyholder and contract holder account maintained by the entity.", "label": "Policyholder Accounts, Policy [Policy Text Block]", "terseLabel": "Separate Accounts" } } }, "localname": "PolicyholderAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredGross": { "auth_ref": [ "r325" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 1.0, "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred.", "label": "Policyholder Benefits and Claims Incurred, Direct", "terseLabel": "Direct" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare": { "auth_ref": [ "r325" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.", "label": "Policyholder Benefits and Claims Incurred, Net, Health", "terseLabel": "Benefit costs", "verboseLabel": "Benefit costs" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredHealthCare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": { "auth_ref": [ "r296", "r325" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.", "label": "Policyholder Benefits and Claims Incurred, Net", "totalLabel": "Net benefit costs" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Policyholder Benefits and Claims Incurred, Net [Abstract]", "terseLabel": "Policyholder Benefits and Claims Incurred, Net [Abstract]" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PolicyholderFunds": { "auth_ref": [ "r1020", "r1024", "r1025", "r1188" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount due to policyholder. Includes, but is not limited to, unpaid policy dividend, retrospective refund, and undistributed earnings on participating business. Excludes future policy benefit and claim expense.", "label": "Policyholder Account Balance", "periodEndLabel": "Policyholders\u2019 funds, end of the period", "periodStartLabel": "Policyholders\u2019 funds, beginning of the period" } } }, "localname": "PolicyholderFunds", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofPolicyholdersFundsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r862" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r33", "r625" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r33", "r625" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r33", "r1173" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsEarnedNet": { "auth_ref": [ "r965", "r989", "r1000", "r1046" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.", "label": "Premiums Earned, Net", "terseLabel": "Premiums", "totalLabel": "Net premiums" } } }, "localname": "PremiumsEarnedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsReceivableAtCarryingValue": { "auth_ref": [ "r312" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": 3.0, "parentTag": "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.", "label": "Premiums Receivable, Net", "terseLabel": "Premium receivables" } } }, "localname": "PremiumsReceivableAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivateEquityFundsMember": { "auth_ref": [ "r1296" ], "lang": { "en-us": { "role": { "documentation": "Investments held in private equity funds.", "label": "Private Equity Funds [Member]", "verboseLabel": "Private equity investments" } } }, "localname": "PrivateEquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r89" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Cash receipts from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r402" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Proceeds from debt" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "verboseLabel": "Proceeds from divestiture of subsidiary" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "auth_ref": [ "r79" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "terseLabel": "Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,854, $0 and $9)" } } }, "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInterestAndDividendsReceived": { "auth_ref": [ "r405", "r409" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for dividends and interest on the entity's equity and debt investments during the current period.", "label": "Proceeds from Interest and Dividends Received", "terseLabel": "Interest and investment income received" } } }, "localname": "ProceedsFromInterestAndDividendsReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r84" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity": { "auth_ref": [ "r970" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from principal payment received from sales-type and direct financing leases classified as investing activity.", "label": "Proceeds from Lease Payment, Sales-Type and Direct Financing Leases, Investing Activity", "terseLabel": "Proceeds from sale-leaseback transactions" } } }, "localname": "ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r1214", "r1215" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r78", "r124", "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r83", "r208" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "verboseLabel": "Cash received from stock options exercised (including ESPP)" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r1293" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsChangesinBalancesofLongDurationInsuranceLiabilitiesDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r1148" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Products" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r360", "r386", "r389", "r407", "r415", "r427", "r439", "r440", "r475", "r486", "r492", "r495", "r526", "r584", "r585", "r587", "r588", "r589", "r591", "r593", "r595", "r596", "r824", "r827", "r828", "r846", "r864", "r971", "r1135", "r1170", "r1171", "r1211", "r1284" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": { "auth_ref": [ "r1340" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant, and Equipment, Fair Value Disclosure", "terseLabel": "Property and equipment, fair value" } } }, "localname": "PropertyPlantAndEquipmentFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r156", "r366" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r158", "r310", "r978", "r1173" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r158", "r1085", "r1086" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life of property plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PropertySubjectToOperatingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property subject to an operating lease.", "label": "Property Subject to Operating Lease [Member]", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "PropertySubjectToOperatingLeaseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by property that could be leased or is available for lease.", "label": "Property Subject to or Available for Operating Lease [Axis]", "terseLabel": "Property Subject to or Available for Operating Lease [Axis]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "A descriptive title of whether the property is subject to or available for operating lease.", "label": "Property Subject to or Available for Operating Lease [Domain]", "terseLabel": "Property Subject to or Available for Operating Lease [Domain]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstateFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments in funds that invest in commercial or residential real estate.", "label": "Real Estate Funds [Member]", "verboseLabel": "Real estate partnerships" } } }, "localname": "RealEstateFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstateInvestmentMember": { "auth_ref": [ "r1071", "r1072", "r1073", "r1193" ], "lang": { "en-us": { "role": { "documentation": "This element represents direct equity investments in real estate projects (Land, buildings and improvements owned for income production and capital accretion potential) and certain loans accounted for as real estate investments. For loans accounted for as real estate investments, the entity (lender) has virtually the same risks and rewards as those of owners or joint venture participants. Such arrangements are treated as if the entity actually has an ownership interest in the property. In such arrangements, the entity (lender) participates in expected residual profits, which may be in the form of an equity kicker or a higher than usual effective interest rate. At the outset and during the construction and development of the property, the borrower generally has little or no equity in the property and the entity's (lender's) only source of repayment is the property. The entity (lender) generally (a) agrees to provide substantially all funds to acquire, develop, and construct the property, (b) funds the commitment or origination fees or both, and (c) funds interest during the development and construction of the property.", "label": "Real Estate Investment [Member]", "terseLabel": "Real estate investment" } } }, "localname": "RealEstateInvestmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r324" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Net realized capital (gains) losses", "terseLabel": "Net realized capital gains (losses)" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r1245", "r1246", "r1247", "r1248" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r63", "r393", "r873", "r877", "r879", "r1209" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "terseLabel": "Amounts reclassified, pre-tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r63", "r65", "r393", "r873", "r877", "r879", "r1209" ], "calculation": { "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss), net of tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "Changes in Accumulated Other Comprehensive Income (Loss) by Component" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r117", "r120" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation Of Consolidated Operating Income to Adjusted Operating Income" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable": { "auth_ref": [ "r118", "r120" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of a significant segment item of information disclosed (for example, liabilities) other than profit (loss), revenues, or assets, between reportable segments in total and the entity's consolidated total for that significant segment item disclosed.", "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemablePreferredStockMember": { "auth_ref": [ "r25", "r172", "r415", "r526", "r584", "r587", "r588", "r589", "r595", "r596", "r864" ], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series.", "label": "Redeemable Preferred Stock [Member]", "terseLabel": "Redeemable preferred securities" } } }, "localname": "RedeemablePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReinsuranceAccountingPolicy": { "auth_ref": [ "r1057", "r1189", "r1190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.", "label": "Reinsurance Accounting Policy [Policy Text Block]", "terseLabel": "Reinsurance Recoverables" } } }, "localname": "ReinsuranceAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReinsuranceDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reinsurance Disclosures [Abstract]", "terseLabel": "Reinsurance Disclosures [Abstract]" } } }, "localname": "ReinsuranceDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed": { "auth_ref": [ "r296" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 2.0, "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of policy benefits and costs incurred for policies assumed.", "label": "Policyholder Benefits and Claims Incurred, Assumed", "terseLabel": "Assumed" } } }, "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded": { "auth_ref": [ "r296" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 3.0, "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reduction of provision for policy benefits and costs incurred for policies ceded.", "label": "Policyholder Benefits and Claims Incurred, Ceded", "negatedTerseLabel": "Ceded" } } }, "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Premiums Earned, Net [Abstract]", "terseLabel": "Premiums Earned, Net [Abstract]" } } }, "localname": "ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": { "auth_ref": [ "r327", "r330", "r1360", "r1364" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "weight": -1.0 }, "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.", "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments", "periodEndLabel": "Add: Reinsurance recoverables", "periodStartLabel": "Less: Reinsurance recoverables", "terseLabel": "Reinsurance recoverables" } } }, "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses": { "auth_ref": [ "r983", "r1007", "r1008", "r1055" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, policy benefits and policy reserves. Excludes premiums paid under reinsurance contracts.", "label": "Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments", "terseLabel": "Total reinsurance recoverables" } } }, "localname": "ReinsuranceRecoverablesOnPaidAndUnpaidLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceTextBlock": { "auth_ref": [ "r981", "r982", "r1057", "r1189", "r1190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts.", "label": "Reinsurance [Text Block]", "terseLabel": "Reinsurance" } } }, "localname": "ReinsuranceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/Reinsurance" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r272" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expenses from transactions with related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "Related Party Transaction, Other Revenues from Transactions with Related Party", "terseLabel": "Other revenues from transactions with related party" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r86" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayments of long-term debt", "terseLabel": "Redeemed principal amount" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r567", "r568", "r1140" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]", "terseLabel": "Reporting Unit [Axis]" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [ "r567", "r568", "r1140" ], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]", "terseLabel": "Reporting Unit [Domain]" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "auth_ref": [ "r1249", "r1296" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by residential real estate mortgage loans.", "label": "Residential Mortgage-Backed Securities [Member]", "terseLabel": "Residential mortgage-backed securities" } } }, "localname": "ResidentialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r1206", "r1220" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash (included in other current assets)" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r1079", "r1207", "r1220" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash (included in other assets)" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r347", "r1067", "r1078", "r1080" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Investments related to 2012 contract conversion" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r36", "r178", "r306", "r1032", "r1037", "r1173" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r355", "r423", "r424", "r425", "r428", "r437", "r440", "r531", "r773", "r774", "r775", "r806", "r807", "r844", "r1028", "r1030" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r184", "r185", "r656", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r704", "r705", "r706", "r708", "r711", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r728", "r729", "r730", "r733", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r184", "r185", "r656", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r704", "r705", "r706", "r708", "r711", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r728", "r729", "r730", "r733", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r466", "r467", "r485", "r490", "r491", "r497", "r498", "r500", "r652", "r653", "r957" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Intersegment revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r655", "r1131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r396", "r415", "r466", "r467", "r485", "r490", "r491", "r497", "r498", "r500", "r526", "r584", "r585", "r587", "r588", "r589", "r591", "r593", "r595", "r596", "r864", "r971", "r1284" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r906", "r1172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r906", "r1172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleAndLeasebackTransactionGainLossNet": { "auth_ref": [ "r904", "r913", "r1172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.", "label": "Sale and Leaseback Transaction, Gain (Loss), Net", "terseLabel": "Gains from sale-leaseback transactions" } } }, "localname": "SaleAndLeasebackTransactionGainLossNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "auth_ref": [ "r1154" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred directly to consumer.", "label": "Sales Channel, Directly to Consumer [Member]", "terseLabel": "Mail choice" } } }, "localname": "SalesChannelDirectlyToConsumerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesChannelThroughIntermediaryMember": { "auth_ref": [ "r1154" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred through intermediary.", "label": "Sales Channel, Through Intermediary [Member]", "terseLabel": "Pharmacy network" } } }, "localname": "SalesChannelThroughIntermediaryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r500", "r1241" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenues" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of accounts receivable, net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r63", "r1343", "r1344" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Changes in Fair Value of Plan Assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "terseLabel": "Schedule of Assets (Liabilities) Recognized in Balance Sheet" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Weighted Average Assumptions Used in Determining Benefit Obligations and Net Benefit Costs" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r217", "r218", "r820" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of reconciliation of cash and cash equivalents" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock": { "auth_ref": [ "r1375" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.", "label": "Ceded Credit Risk [Table Text Block]", "terseLabel": "Schedule of Reinsurance Recoverables" } } }, "localname": "ScheduleOfCededCreditRiskByReinsurerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Changes in Plan Assets" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.", "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]", "terseLabel": "Schedule of Changes in Benefit Obligations" } } }, "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Income Tax Provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r48", "r174", "r175", "r176", "r177", "r268", "r269", "r271", "r295", "r1143", "r1145", "r1224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Summary of Company's Borrowings" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r193", "r194", "r195", "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r8", "r9", "r10", "r11", "r12", "r13", "r16", "r18", "r19", "r20", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of discontinued operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r1240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Reconciliation of Basic and Diluted Earnings (Loss) Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r206", "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Expected Future Benefits Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r849", "r850" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Separate Account Investment [Line Items]", "terseLabel": "Fair Value, Separate Account Investment [Line Items]" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable": { "auth_ref": [ "r1174", "r1191", "r1372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset supporting separate account.", "label": "Fair Value, Separate Account Investment [Table]", "terseLabel": "Fair Value, Separate Account Investment [Table]" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock": { "auth_ref": [ "r297", "r1191", "r1372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of asset supporting separate account.", "label": "Fair Value, Separate Account Investment [Table Text Block]", "terseLabel": "Summary of Separate Account Assets", "verboseLabel": "Schedule of Fair Value of Separate Accounts by Major Category of Investment" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueTables", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r1140" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r1140", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of Changes in Carrying Amount of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Net Investment Income [Line Items]", "terseLabel": "Schedule of Investment Income, Reported Amounts, by Category [Line Items]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "auth_ref": [ "r74", "r75", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table]", "terseLabel": "Schedule of Investment Income, Reported Amounts, by Category [Table]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "terseLabel": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense and Components of Change in Health Care Costs Payable" } } }, "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-Term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Periodic Benefit Cost (Income)" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r101", "r102", "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Schedule of Adjustments Resulting From Applying New Accounting Standard" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "RSU and Performance Share Unit Activity" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRegulatoryAssetsTextBlock": { "auth_ref": [ "r349", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets that are created when regulatory agencies permit public utilities to defer certain costs included in rate-setting to the balance sheet.", "label": "Schedule of Regulatory Assets [Table Text Block]", "terseLabel": "Schedule of Regulatory Requirements" } } }, "localname": "ScheduleOfRegulatoryAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r115", "r116", "r119", "r138" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r115", "r116", "r119", "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Summarized Financial Information Of Segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r735", "r736", "r739", "r740", "r741", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r763", "r764", "r765", "r766", "r767" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Options and Stock Appreciation Rights Award Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule ESPP Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r179", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Share Repurchase Programs" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "verboseLabel": "Schedule of Debt Securities In An Unrealized Capital Loss Position" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r1169", "r1328" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of Unrecognized Tax Benefits Rollforward" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r233", "r235", "r238", "r239", "r240", "r825", "r826", "r831", "r832", "r936", "r937", "r938" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "auth_ref": [ "r233", "r235", "r238", "r239", "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table Text Block]", "terseLabel": "Schedule of variable interest entities" } } }, "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "verboseLabel": "Schedule of Projected Annual Amortization Expense for Intangible Assets for Next Five Years" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r463", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r495", "r500", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r575", "r576", "r1140", "r1365" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r463", "r464", "r465", "r475", "r478", "r489", "r493", "r494", "r495", "r496", "r497", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Other Significant Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Other Significant Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingOtherSignificantReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r479", "r480", "r481", "r482", "r483", "r484", "r498" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SelfInsuranceReserve": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Self Insurance Reserve", "terseLabel": "Self insurance liabilities" } } }, "localname": "SelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReservePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).", "label": "Self Insurance Reserve [Policy Text Block]", "terseLabel": "Self-Insurance Liabilities" } } }, "localname": "SelfInsuranceReservePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeparateAccountAssetCategoryAxis": { "auth_ref": [ "r1048", "r1191" ], "lang": { "en-us": { "role": { "documentation": "Information by separate account asset investment.", "label": "Separate Account Asset Category [Axis]", "terseLabel": "Separate Account Asset Category [Axis]" } } }, "localname": "SeparateAccountAssetCategoryAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeparateAccountAssetCategoryDomain": { "auth_ref": [ "r1048", "r1191" ], "lang": { "en-us": { "role": { "documentation": "Separate account asset investment.", "label": "Separate Account Asset Category [Domain]", "terseLabel": "Separate Account Asset Category [Domain]" } } }, "localname": "SeparateAccountAssetCategoryDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeparateAccountAssets": { "auth_ref": [ "r985", "r1047", "r1048", "r1191" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset at fair value held for benefit of separate account policyholder.", "label": "Separate Account Asset", "terseLabel": "Separate accounts assets" } } }, "localname": "SeparateAccountAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeparateAccountCashAndCashEquivalentsMember": { "auth_ref": [ "r1191", "r1372" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent in which separate account asset is invested.", "label": "Separate Account, Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "SeparateAccountCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeparateAccountDebtSecurityMember": { "auth_ref": [ "r1372" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporation, government, or governmental agency, municipality, and other institution; in which separate account asset is invested.", "label": "Separate Account, Debt Security [Member]", "terseLabel": "Debt securities" } } }, "localname": "SeparateAccountDebtSecurityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeparateAccountLiabilityBenefitPayment": { "auth_ref": [ "r1192", "r1373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to separate account policyholder from benefit payment.", "label": "Separate Account, Liability, Benefit Payment", "negatedTerseLabel": "Benefit payments" } } }, "localname": "SeparateAccountLiabilityBenefitPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeparateAccountLiabilityCashSurrenderValueAmount": { "auth_ref": [ "r1050", "r1192" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of separate account liability payable to policyholder upon surrender of contract before maturity.", "label": "Separate Account, Liability, Cash Surrender Value, Amount", "terseLabel": "Cash surrender value, end of the period" } } }, "localname": "SeparateAccountLiabilityCashSurrenderValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance": { "auth_ref": [ "r1192", "r1373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in separate account liability from performance of investment.", "label": "Separate Account, Liability, Increase (Decrease) from Invested Performance", "terseLabel": "Investment earnings" } } }, "localname": "SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeparateAccountLiabilityIncreaseDecreaseFromOtherChange": { "auth_ref": [ "r1192", "r1373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount increase (decrease) in separate account liability from change, classified as other.", "label": "Separate Account, Liability, Increase (Decrease) from Other Change", "terseLabel": "Other" } } }, "localname": "SeparateAccountLiabilityIncreaseDecreaseFromOtherChange", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeparateAccountLiabilityPremiumAndDeposit": { "auth_ref": [ "r1192", "r1373" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow to separate account liability from premium and deposit from cash received.", "label": "Separate Account, Liability, Premium and Deposit", "terseLabel": "Premiums and deposits" } } }, "localname": "SeparateAccountLiabilityPremiumAndDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeparateAccountLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Separate Account, Liability [Roll Forward]", "terseLabel": "Separate Account, Liability [Roll Forward]" } } }, "localname": "SeparateAccountLiabilityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeparateAccountLiabilitySurrenderAndWithdrawal": { "auth_ref": [ "r1192", "r1373" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in separate account liability from contract redemption and withdrawal of funds.", "label": "Separate Account, Liability, Surrender and Withdrawal", "negatedTerseLabel": "Surrenders and withdrawals" } } }, "localname": "SeparateAccountLiabilitySurrenderAndWithdrawal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeparateAccountLiabilityTableTextBlock": { "auth_ref": [ "r1052", "r1192" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about separate account liability, including, but not limited to change in liability and related cash surrender value.", "label": "Separate Account, Liability [Table Text Block]", "terseLabel": "Roll Forward of Separate Accounts" } } }, "localname": "SeparateAccountLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeparateAccountMortgageBackedSecurityMember": { "auth_ref": [ "r1372", "r1374" ], "lang": { "en-us": { "role": { "documentation": "Security collateralized by real estate mortgage loan, in which separate account asset is invested.", "label": "Separate Account, Mortgage-Backed Security [Member]", "terseLabel": "Mortgage-backed securities" } } }, "localname": "SeparateAccountMortgageBackedSecurityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeparateAccountsLiability": { "auth_ref": [ "r986", "r1047", "r1049", "r1051", "r1192" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for variable contract in which all or portion of contract holder's funds is allocated to specific separate account and supported by assets held in separate account.", "label": "Separate Account, Liability", "negatedTerseLabel": "Separate accounts liabilities", "periodEndLabel": "Separate Accounts liability, end of the period", "periodStartLabel": "Separate Accounts liability, beginning of the period", "terseLabel": "Separate accounts liabilities" } } }, "localname": "SeparateAccountsLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r1148" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Services" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [ "r1276" ], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r92" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r1166" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r756" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r756" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r754" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r754" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Weighted-average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at end of period (in shares)", "periodStartLabel": "Unvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at end of year (in dollars per share)", "periodStartLabel": "Unvested at beginning of year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r758" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Vested in period, fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r765" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r764" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r766" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r1168" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r745" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Shares exercisable at end of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r745" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price exercisable at end of year ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r758" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of stock options and SARs exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r750" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Shares expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r749" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Shares forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Shares granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic value outstanding at end of year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r743", "r744" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares, Outstanding at end of year (in shares)", "periodStartLabel": "Shares, Outstanding at beginning of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r743", "r744" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, outstanding at end of year ($ per share)", "periodStartLabel": "Weighted average exercise price, outstanding at beginning of year ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r759" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value vested at end of year and expected to vest in the future" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Shares vested at end of year and expected to vest in the future (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price vested at end of year and expected to vest in the future ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r739", "r740", "r741", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r763", "r764", "r765", "r766", "r767" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercised ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r750" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, expired ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r749" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, forfeited ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, granted ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r742", "r761", "r762", "r763", "r764", "r767", "r776", "r777" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r1167" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r763" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value exercisable at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term exercisable at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average contractual term, outstanding at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term vested at end of year and expected to vest in the future" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares outstanding, end of year balance (in shares)", "periodStartLabel": "Shares outstanding, beginning of year balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2019Member": { "auth_ref": [ "r1012" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2019 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2019 [Member]", "terseLabel": "2021" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2019Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2020Member": { "auth_ref": [ "r1012" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2020 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2020 [Member]", "terseLabel": "2022" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2020Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r26", "r278", "r305", "r1173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-Term Debt", "terseLabel": "Short-term debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]", "terseLabel": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r283", "r284", "r302", "r1208" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_Investments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Investments", "verboseLabel": "Current" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r901", "r1172" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease costs" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-Duration Insurance Contracts, Accident Year [Axis]", "terseLabel": "Short-duration Insurance Contracts, Accident Year [Axis]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-Duration Insurance Contracts, Accident Year [Domain]", "terseLabel": "Short-duration Insurance Contracts, Accident Year [Domain]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts.", "label": "Short-Duration Insurance Contracts, Claims Development [Table]", "terseLabel": "Short-duration Insurance Contracts, Claims Development [Table]" } } }, "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.", "label": "Short-Duration Insurance Contracts, Claims Development [Table Text Block]", "terseLabel": "Information about Incurred and Paid Health Care Claims Development" } } }, "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet": { "auth_ref": [ "r333" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": { "order": 1.0, "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net", "terseLabel": "Cumulative Paid Health Care Claims, Net of Reinsurance" } } }, "localname": "ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet": { "auth_ref": [ "r336", "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of incurred-but-not-reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net", "verboseLabel": "Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) claims liability, net" } } }, "localname": "ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet": { "auth_ref": [ "r332" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": { "order": 3.0, "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net", "terseLabel": "Incurred Health Care Claims, Net of Reinsurance" } } }, "localname": "ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet": { "auth_ref": [ "r334", "r335" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net", "terseLabel": "Short-duration health care costs payable, net of reinsurance", "totalLabel": "Total outstanding liabilities for health care costs payable, net of reinsurance" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented": { "auth_ref": [ "r334" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": { "order": 2.0, "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts for accident years not separately presented in claim development information. Excludes unallocated claim adjustment expense.", "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented", "terseLabel": "All outstanding liabilities for health care costs payable prior to 2021, net of reinsurance" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem": { "auth_ref": [ "r335" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reconciling item for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts, classified as other.", "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item", "terseLabel": "Insurance lines other than short duration" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]", "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]", "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r358", "r463", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r495", "r500", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r574", "r575", "r576", "r1140", "r1365" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SegmentReportingRetrospectiveAdjustmentstoSegmentCompositionDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r53", "r173", "r355", "r392", "r393", "r394", "r423", "r424", "r425", "r428", "r437", "r440", "r458", "r531", "r640", "r773", "r774", "r775", "r806", "r807", "r844", "r873", "r874", "r875", "r876", "r877", "r879", "r919", "r1028", "r1029", "r1030" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r423", "r424", "r425", "r458", "r957" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StatutoryAccountingPracticesDisclosureTextBlock": { "auth_ref": [ "r316", "r341", "r342", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of how the entity's reporting under GAAP as of the balance sheet date differs from the results based on prescribed and permitted accounting practices of the state or country of domicile in which a relevant statutory filing is made, or differences in results based on the National Association of Insurance Commissioners (NAIC) prescribed practices, or a combination thereof. Describes the accounting practices used and the related monetary effect on statutory surplus, net income, and risk-based capital. If an insurance enterprise's risk-based capital would have triggered a regulatory event had it not used a permitted practice, that fact is disclosed in the financial statements. Permitted statutory accounting practices include practices not prescribed but allowed by the domiciliary state insurance department regulatory authority.", "label": "Statutory Accounting Practices Disclosure [Table Text Block]", "terseLabel": "Statutory Accounting Practices Disclosure" } } }, "localname": "StatutoryAccountingPracticesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatutoryAccountingPracticesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statutory Accounting Practices [Line Items]", "terseLabel": "Statutory Accounting Practices [Line Items]" } } }, "localname": "StatutoryAccountingPracticesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of dividends that can be declared or paid without approval of regulatory agency.", "label": "Statutory Accounting Practices, Statutory Amount Available for Dividend Payments without Regulatory Approval", "terseLabel": "Estimated maximum dividend distributions permitted in 2023 without prior regulatory approval" } } }, "localname": "StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance": { "auth_ref": [ "r307", "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.", "label": "Statutory Accounting Practices, Statutory Capital and Surplus, Balance", "terseLabel": "Estimated statutory capital and surplus" } } }, "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": { "auth_ref": [ "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.", "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required", "terseLabel": "Estimated minimum statutory surplus required by regulators" } } }, "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount": { "auth_ref": [ "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of net income for the period determined using accounting principles prescribed or permitted by insurance regulators.", "label": "Statutory Accounting Practices, Statutory Net Income Amount", "terseLabel": "Statutory net income" } } }, "localname": "StatutoryAccountingPracticesStatutoryNetIncomeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesTable": { "auth_ref": [ "r316", "r341", "r342", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Detail by state, country, or other jurisdiction of domicile in which financial statements are filed reflecting statutory capital and surplus, net income and the differences between financial reports which are in conformity with generally accepted accounting principles and the statutory financial statements which also use state permitted or prescribed accounting practices.", "label": "Statutory Accounting Practices [Table]", "terseLabel": "Statutory Accounting Practices [Table]" } } }, "localname": "StatutoryAccountingPracticesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r33", "r34", "r173", "r178" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r33", "r34", "r173", "r178", "r748" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Shares exercised (in shares)", "verboseLabel": "Stock option activity, stock awards and other (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r53", "r173", "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option activity, stock awards and other" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r33", "r34", "r173", "r178" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Stock repurchased during the period (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r33", "r34", "r173", "r178" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "terseLabel": "Stock repurchased during period, value" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r34", "r37", "r38", "r123", "r1173", "r1222", "r1257", "r1342" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "terseLabel": "Total CVS Health shareholders\u2019 equity", "totalLabel": "Total CVS Health shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r224", "r225", "r241", "r355", "r356", "r393", "r423", "r424", "r425", "r428", "r437", "r531", "r640", "r773", "r774", "r775", "r806", "r807", "r844", "r873", "r874", "r879", "r919", "r1029", "r1030", "r1222", "r1257", "r1342" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "negatedTerseLabel": "Reduction to retained earnings as a result of new accounting standard adoption", "periodEndLabel": "End of year balance", "periodStartLabel": "Beginning of year balance", "terseLabel": "Total shareholders\u2019 equity", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r183", "r414", "r626", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r639", "r640", "r835" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r903", "r1172" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Less: sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r880", "r921" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r880", "r921" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r880", "r921" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails", "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalIncomeStatementElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Income Statement Elements [Abstract]", "terseLabel": "Condensed Consolidated Statement of Operations:" } } }, "localname": "SupplementalIncomeStatementElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsAdjustmentsResultingFromApplyingNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r1010" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.", "label": "Current Year Claims and Claims Adjustment Expense", "terseLabel": "Current year" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r1010" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.", "label": "Prior Year Claims and Claims Adjustment Expense", "negatedTerseLabel": "Decrease in prior years' healthcare costs payable", "verboseLabel": "Prior years" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferToFromPolicyholderAccountBalanceToFromSeparateAccount": { "auth_ref": [ "r1185", "r1188", "r1192", "r1367", "r1373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer to (from) liability for policyholder account balance (to) from liability for separate account.", "label": "Transfer to (from) Policyholder Account Balance (to) from Separate Account", "terseLabel": "Net transfers from general account" } } }, "localname": "TransferToFromPolicyholderAccountBalanceToFromSeparateAccount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsRollForwardofSeparateAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r515", "r516", "r622", "r638", "r834", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r1254", "r1255", "r1256", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Shares" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "negatedPeriodEndLabel": "Treasury shares outstanding, end of year balance (in shares)", "negatedPeriodStartLabel": "Treasury shares outstanding, beginning of year balance (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r52", "r179" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r52", "r179", "r182" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost: 458 and 422 shares at December\u00a031, 2022 and 2021" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r353", "r354", "r355", "r356", "r357", "r427", "r428", "r429", "r430", "r441", "r505", "r506", "r528", "r529", "r530", "r531", "r532", "r533", "r773", "r774", "r775", "r804", "r805", "r806", "r807", "r821", "r822", "r823", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r882", "r883", "r886", "r887", "r888", "r889", "r914", "r915", "r916", "r917", "r918", "r919", "r959", "r960", "r961", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r1293" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible Enumeration]", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r1132", "r1155", "r1358" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "auth_ref": [ "r1155", "r1372" ], "lang": { "en-us": { "role": { "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.", "label": "US States and Political Subdivisions Debt Securities [Member]", "terseLabel": "States, municipalities and political subdivisions", "verboseLabel": "States, municipalities and political subdivisions" } } }, "localname": "USStatesAndPoliticalSubdivisionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/OtherInsuranceLiabilitiesandSeparateAccountsSeparateAccountAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r972", "r1155", "r1372" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy": { "auth_ref": [ "r1009", "r1011" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.", "label": "Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]", "terseLabel": "Other Insurance Liabilities" } } }, "localname": "UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r780", "r789" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r790" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Reductions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r792" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r788" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Income tax penalties and interest accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r788" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Income tax penalties and interest expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r791" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r790" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions based on tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r793" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Expiration of statutes of limitation" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r794" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r112", "r113", "r114", "r459", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Valuation Allowance [Line Items]", "terseLabel": "Valuation Allowance [Line Items]" } } }, "localname": "ValuationAllowanceLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceTable": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.", "label": "Valuation Allowance [Table]", "terseLabel": "Valuation Allowance [Table]" } } }, "localname": "ValuationAllowanceTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Not Primary Beneficiary" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "VIE, ownership percentage" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r902", "r1172" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r443", "r451" ], "calculation": { "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average diluted shares outstanding (in shares)", "totalLabel": "Weighted average shares, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r442", "r451" ], "calculation": { "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average basic shares outstanding (in shares)", "verboseLabel": "Weighted average shares, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "terseLabel": "Write off of deferred debt issuance cost" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 15 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1000": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1001": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1002": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=35755530&loc=d3e11264-158415", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1003": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1004": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1005": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1006": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org/subtopic&trid=4737841", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1007": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21409-158489", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1008": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1009": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14754-158437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1010": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1011": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14784-158437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1012": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1013": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1016": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1017": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(5)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1018": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(6)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1019": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1020": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1021": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1022": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1023": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1024": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1025": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1026": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1027": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1028": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1029": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1030": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1031": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1032": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1033": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1034": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1035": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1036": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1037": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1038": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/subtopic&trid=2560295", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1039": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "605", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=84167274&loc=d3e27175-158546", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1040": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(a)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1041": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(b)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1042": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(b)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1043": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(b)(3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1044": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1045": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1046": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1047": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "80", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6484091&loc=d3e19268-158472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1048": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1049": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e725-108305", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1050": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1051": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1052": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1053": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506110&loc=d3e32546-158582", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1054": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600598&loc=SL75763979-209797", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1055": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1056": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1057": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "944", "URI": "https://asc.fasb.org/topic&trid=2303980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1058": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1059": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e765-108305", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1060": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1061": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1062": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1063": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1064": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1065": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1066": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1067": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1068": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1069": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1070": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1071": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1072": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1073": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1074": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Column G))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1075": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1076": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 6))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1077": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29)", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1078": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1079": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1080": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1081": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1082": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1083": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1084": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=49178521&loc=d3e9162-115647", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1085": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1086": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1087": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1088": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1089": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1090": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1091": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1092": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1093": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1094": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1095": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1096": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1097": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1098": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1099": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1100": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1101": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1102": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1103": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1104": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1105": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1106": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1107": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1108": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1109": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1110": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1111": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1112": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1113": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1114": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1115": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "01", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1116": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1117": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "01", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1118": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1119": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(C)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1120": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1121": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1122": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1126": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1127": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1129": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3505-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1133": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1135": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1136": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1137": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921842-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1138": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1140": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1143": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1144": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1145": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1146": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1148": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1149": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1150": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1151": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1152": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1153": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1154": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1157": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1162": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1169": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1170": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1171": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1172": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1173": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124504731&loc=d3e11522-158419", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1176": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1177": { "Name": "Accounting Standards Codification", "Paragraph": "13I", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1178": { "Name": "Accounting Standards Codification", "Paragraph": "13I", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1179": { "Name": "Accounting Standards Codification", "Paragraph": "13I", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1180": { "Name": "Accounting Standards Codification", "Paragraph": "13I", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1181": { "Name": "Accounting Standards Codification", "Paragraph": "13I", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1182": { "Name": "Accounting Standards Codification", "Paragraph": "13I", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(g)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1183": { "Name": "Accounting Standards Codification", "Paragraph": "13I", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(h)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1184": { "Name": "Accounting Standards Codification", "Paragraph": "13J", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783734-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1185": { "Name": "Accounting Standards Codification", "Paragraph": "13J", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783734-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1186": { "Name": "Accounting Standards Codification", "Paragraph": "13J", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(g)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783734-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1187": { "Name": "Accounting Standards Codification", "Paragraph": "29E", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819541-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1188": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1189": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "605", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99379264&loc=d3e27758-158548", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "605", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99379264&loc=d3e27830-158548", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1191": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124505678&loc=SL117422397-158474", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1192": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124505678&loc=SL117422401-158474", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1193": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1194": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1195": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1196": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r1197": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1198": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1199": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1200": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1201": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1202": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1203": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1204": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r1205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r1206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1212": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1214": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1215": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1216": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1217": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1218": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1219": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953659-111524", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1225": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1226": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1231": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1232": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1233": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1236": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1237": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1241": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1242": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1244": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1252": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1275": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1278": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1289": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1290": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1291": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1293": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1299": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450678-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1327": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1328": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1331": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1332": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1335": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1337": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1342": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1343": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1347": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1350": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1351": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1360": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(6))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1363": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1364": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1365": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1367": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1368": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1369": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1370": { "Name": "Accounting Standards Codification", "Paragraph": "9C", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=122147696&loc=SL65671395-207642", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1374": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124505678&loc=SL117422397-158474", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1375": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1376": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1377": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1378": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1379": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1380": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1381": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1382": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1383": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1384": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1385": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(ii)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1386": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1387": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1388": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2599-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6479118&loc=d3e64650-112822", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),5)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.14)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.23(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.5)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=35755530&loc=d3e11264-158415", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(cc)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671317-158438", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671321-158438", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6483535&loc=d3e16392-158451", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24746-158529", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24790-158529", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "505", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=82848697&loc=d3e24938-158530", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "505", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=82848697&loc=d3e24959-158530", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r348": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "980", "URI": "https://asc.fasb.org/extlink&oid=6499975&loc=d3e44250-110382", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "980", "URI": "https://asc.fasb.org/extlink&oid=6499975&loc=d3e44264-110382", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "715", "Topic": "980", "URI": "https://asc.fasb.org/extlink&oid=6501251&loc=d3e52485-110419", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(m)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(b))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22 (b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r819": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r881": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r911": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919786-209982", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(c))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r967": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r968": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r969": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r970": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=SL120154370-112784", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r971": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r972": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r973": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r974": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r975": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r976": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(d)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r977": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r978": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r979": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6480726&loc=d3e6691-158385", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r980": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6480726&loc=d3e6691-158385", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r981": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r982": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6816-158387", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r983": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r984": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r985": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r986": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r987": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r988": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(7))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r989": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r990": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r991": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r992": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r993": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r994": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r995": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(7)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r996": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r997": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r998": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r999": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" }